<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Current Drug Delivery via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Current Drug Delivery' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Current+Drug+Delivery&t=Current+Drug+Delivery&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 14:04:07 +0100</lastBuildDate>
        <item>
            <title>Development and Characterization of Self-nanoemulsifying Drug Delivery Systems (SNEDDS) of Atorvastatin Calcium.</title>
            <link>http://www.medworm.com/index.php?rid=5643710&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283646%26dopt%3DAbstract</link>
            <description>Authors: Mantri SK, Pashikanti S, Murthy KR
    Abstract
    optimized. FT-IR and DSC were studied for interaction between drug and excipients if any. Forced degradation and accelerated stability studies were conducted for optimized SNEDDS. ATVF 04 and 11 were selected as optimized SNEDDS due to their smaller mean globule size (75.2 and 85.8 nm respectively), lower turbidity values, faster drug release and higher DE values among the other SNEDDS. The optimized ATV SNEDDS were not affected by the pH of dilution medium. FT-IR study revealed no interaction between drug and excipients used. Forced degradation studies indicated the stability of ATV in the gastric environment. Accelerated stability studies showed no significant changes in the mean globule size, zeta potential, drug content and d...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643710</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643710</guid>        </item>
        <item>
            <title>Sustained Ocular Delivery of Brimonidine Tartrate using Ion Activated In Situ Gelling System.</title>
            <link>http://www.medworm.com/index.php?rid=5643709&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283647%26dopt%3DAbstract</link>
            <description>Authors: Geethalakshmi A, Karki R, Jha SK, Venkatesh DP, Nikunj B
    Abstract
    study, antibacterial activity, isotonicity testing, eye irritation testing. In the developed formulations Gelrite Brimonidine-3 (GB3) exhibited sustained release of drug from formulation over a period of 8hrs thus increasing residence time of the drug, non-irritating with no ocular damage or abnormal clinical signs to the cornea, iris or conjunctiva, stable and sterile. These results demonstrate that the developed system is an alternative to conventional ophthalmic drops, better patient compliance, industrially oriented and economical.
    PMID: 22283647 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643709</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643709</guid>        </item>
        <item>
            <title>Characterization of the Self Assembly of Methoxy Poly(Ethylene Oxide)-block-Poly(α-Benzyl Carboxylate-ε-Caprolactone) for the Solubilization And In Vivo Delivery of Valspodar.</title>
            <link>http://www.medworm.com/index.php?rid=5643708&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283648%26dopt%3DAbstract</link>
            <description>In conclusion, the results show a potential for PEO-b-PBCL nanocarriers as efficient solubilizing agents for delivery of valspodar.
    PMID: 22283648 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643708</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643708</guid>        </item>
        <item>
            <title>Novel Prodrugs for The Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-Geranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays.</title>
            <link>http://www.medworm.com/index.php?rid=5643707&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283649%26dopt%3DAbstract</link>
            <description>Authors: Epifano F, Genovese S, Carlucci G, Locatelli M
    Abstract
    y for treatment of CRC and on novel prodrugs of 4'-geranyloxyferulic acid and auraptene that were shown to be efficient in vivo as dietary feeding colon cancer chemopreventers in mice.
    PMID: 22283649 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643707</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643707</guid>        </item>
        <item>
            <title>Delivery Methods of Camptothecin And Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer.</title>
            <link>http://www.medworm.com/index.php?rid=5643706&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283650%26dopt%3DAbstract</link>
            <description>Authors: Mollica A, Stefanucci A, Feliciani F, Cacciatore I, Cornacchia C, Pinnen F
    Abstract
    Camptothecins are a family of alkaloids originally extracted from the Chinese tree Camptotheca acuminata, Nyssaceae, exhibiting a strong activity against colorectal cancer (CRC). CRC is a common malignancy worlwide. Despite significant developments in the treatment of this disease, it still causes considerable morbidity and mortality. Recent advances include both newer cytotoxic chemotherapies and novel biological agents including the more hydrosoluble camptothecin derivative, namely irinotecan. Camptothecin and irinotecan are selective human topoisomerase I inhibitors but their application for curing CRC is compromised by their intrinsic high toxicity, insolubility and instability. Further...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643706</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643706</guid>        </item>
        <item>
            <title>Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery.</title>
            <link>http://www.medworm.com/index.php?rid=5643705&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283651%26dopt%3DAbstract</link>
            <description>Authors: Kim H
    Abstract
    The colon is largely being investigated as a site for administration of protein and peptides, which are degraded by digestive enzymes in the upper GIT. Also for local diseases of the colon such as inflammatory bowel disease, colorectal cancer and ameobiasis, drug administration to the site of action can not only reduce the dose to be administered, but also decrease the side effects. Inflammatory Bowel Disease (IBD) such as Ulcerative colitis and Crohn's disease are characterized by chronic intestinal inflammation. Intestinal bacteria initiate the activation of intestinal inflammatory processes, which are mediated by pro-inflammatory cytokines and chemokine. Increased chemokine expression has also been observed in epithelial cells, endothelial cells, and smoo...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643705</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643705</guid>        </item>
        <item>
            <title>Pharmaceutical Plasticizers for Drug Delivery Systems.</title>
            <link>http://www.medworm.com/index.php?rid=5643704&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283652%26dopt%3DAbstract</link>
            <description>Authors: El-Gendy NA
    Abstract
    ticizers.
    PMID: 22283652 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643704</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643704</guid>        </item>
        <item>
            <title>Drug Delivery to the Inner Ear: Strategies and Their Therapeutic Implications for Sensorineural Hearing Loss.</title>
            <link>http://www.medworm.com/index.php?rid=5643703&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283653%26dopt%3DAbstract</link>
            <description>Authors: Rivera T, Sanz L, Camarero G, Varela-Nieto I
    Abstract
    ged drugs). While direct access to the inner ear by intracochlear administration avoids this problem, this method requires surgery. Currently, laboratory animals are being used to explore which therapeutic approaches are best suited to address this problem. These include cochleostomy and the insertion of devices that pump drugs into the inner ear without inducing cochlear damage. In this article, we review the different techniques under evaluation in animal models of deafness, and their potential use for drug delivery and treatment of human inner ear diseases.
    PMID: 22283653 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643703</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643703</guid>        </item>
        <item>
            <title>Cyclodextrins as Oral Drug Carrier Molecular Devices: Origins, Reasons and Applications.</title>
            <link>http://www.medworm.com/index.php?rid=5643702&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283654%26dopt%3DAbstract</link>
            <description>This article highlights the molecular structure, properties like complexation, solubility etc. of cyclodextrins and focuses on its use for oral drug delivery. The objective of this contribution is to focus on the potential use of chemically modified cyclodextrins as high-performance drug carriers in drug delivery systems with emphasis on the more recent developments. Thus cyclodextrins, because of their continuing ability to find several novel applications in drug delivery, are expected to solve many problems associated with the delivery of different novel drugs through different delivery routes.
    PMID: 22283654 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643702</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643702</guid>        </item>
        <item>
            <title>A Rational Design for the Nanoencapsulation of Poisonous Animal Venoms in Liposomes Prepared with Natural Phospholipids.</title>
            <link>http://www.medworm.com/index.php?rid=5643701&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283655%26dopt%3DAbstract</link>
            <description>Authors: da Costa MH, Sant'anna OA, Quintilio W, Schwendener RA, de Araujo PS
    Abstract
    Liposomes have been used since the 1970's to encapsulate drugs envisaging enhancement in efficacy and therapeutic index, avoidance of side effects and increase in the encapsulated agent stability. The major problem when encapsulating snake venoms is the liposomal membrane instability caused by venom phospholipases. Here the results obtained encapsulating Crotalus durissimus terrificus and a pool of Bothropic venoms within liposomes (LC and LB, respectively) used to produce anti-venom sera are presented. The strategy was to modify the immunization protocol to enhance antibody production and to minimize toxic effects by encapsulating inactivated venoms within stabilized liposomes. Chemically modifi...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643701</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643701</guid>        </item>
        <item>
            <title>Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for  Nanoparticle Production.</title>
            <link>http://www.medworm.com/index.php?rid=5643700&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283656%26dopt%3DAbstract</link>
            <description>Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for Nanoparticle Production.
    Curr Drug Deliv. 2012 Jan 5;
    Authors: Sheth P, Sandhu H, Singhal D, Malick W, Shah N, Kislalioglu MS
    Abstract
    only supercritical fluid that is preferentially used in pharmaceutical processes, is not a good solvent for many Active Pharmaceutical Ingredients (API). Various researchers have modified the RESS process to overcome its solubilizing limitations, by introducing RESOLV, RESAS, and RESS-SC. Overall, all RESS based processes are difficult to scale up.  The SAS processes are based on decreasing the solvent power of a polar organic solvent in which the substrate (API &amp;ber of mechanistic studies available. The advantages of especially SAS and PGSS ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643700</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643700</guid>        </item>
        <item>
            <title>The Use of Specific Monoclonal Antibodies to Target Immunogenic Tumor Membrane Proteins in Patients with Recurrent Pancreatic and Colon Cancer.</title>
            <link>http://www.medworm.com/index.php?rid=5643699&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283657%26dopt%3DAbstract</link>
            <description>Authors: Arlen M, Wang X, Luka J, Gupta R, Saric O, Arlen PM
    Abstract
    human pancreatic cancer were then immunized with NPC-1 monoclonal antibody targeting mutated MUC5ac. FDA studies including tissue cross reactivity, biodistribution, and cytokine release assays indicated safety and efficacy of the monoclonals we have developed. Submission of the IND allowed for initiation of the Phase I trial using mAb NPC-1 targeting pancreatic cancer when that antigen was found to be expressed.
    PMID: 22283657 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643699</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643699</guid>        </item>
        <item>
            <title>Lipid Matrix Systems with emphasis on Lipid microspheres: Potent Carriers for Transcutaneous Delivery of Bioactives.</title>
            <link>http://www.medworm.com/index.php?rid=5643698&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22283658%26dopt%3DAbstract</link>
            <description>Authors: Singh MR, Pradhan K, Singh D
    Abstract
    Drug delivery through skin is the major confrontation due to its exceptional barrier properties. Despite major research and development efforts in transdermal systems, low Stratum corneum permeability limits the usefulness of topically administered drugs. This problem is more pronounced with bioactive drugs, which require special formulation technologies to overcome stability issues, their effective localization and safe release. This has led to an increased attention towards effective lipid based topical cutaneous systems. This review provides a brief overview of different lipid based systems, their associated advantages and disadvantages with special emphasis on lipid matrix systems like lipid microspheres or lipospheres and the pote...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5643698</comments>
            <pubDate>Thu, 05 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5643698</guid>        </item>
        <item>
            <title>&quot;Metabolic aspects&quot; in inflammatory bowel diseases.</title>
            <link>http://www.medworm.com/index.php?rid=5362573&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023201%26dopt%3DAbstract</link>
            <description>&quot;Metabolic aspects&quot; in inflammatory bowel diseases.
    Curr Drug Deliv. 2011 Oct 21;
    Authors: Kaser A, Tilg H
    Abstract
    Mesenteric fat hypertrophy is a common feature of inflammatory bowel diseases (IBD), especially Crohn΄s disease. Although this &quot;creeping fat&quot; has been observed in the early days of this disease, its biological relevance is not understood. This adipose tissue has been recognized to release large amounts of various cytokines such as TNFα and adipocytokines such as adiponectin or leptin. Whereas leptin is definitely a pro-inflammatory adipocytokine, the role of the prototypic anti-inflammatory adipocytokine, namely adiponectin, in intestinal inflammation is less clear. Some experimental studies suggest that it could exert also pro-inflammatory activities in the...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362573</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362573</guid>        </item>
        <item>
            <title>Foam preparations for the treatment of ulcerative colitis.</title>
            <link>http://www.medworm.com/index.php?rid=5362572&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023202%26dopt%3DAbstract</link>
            <description>Authors: Loew BJ, Siegel CA
    Abstract
    Patients with ulcerative colitis uniformly have disease involving the distal colon. When patients have disease limited to the left colon or symptoms suggestive of active rectal inflammation, guidelines recommend topical rectal therapies as first-line agents either as monotherapy or in conjunction with oral products. Rectal delivery modalities offer the advantage of delivering high local concentrations of active medication to the site of maximal inflammation with minimization of systemic side effects. Methods of rectal administration include suppositories, liquid enemas and foams. Suppositories are limited to the treatment of rectal disease, and patients often have difficulty retaining the liquid enema secondary to its high volume and consistency...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362572</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362572</guid>        </item>
        <item>
            <title>Cell therapies for inflammatory bowel disease.</title>
            <link>http://www.medworm.com/index.php?rid=5362571&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023203%26dopt%3DAbstract</link>
            <description>Authors: Panés J, García-Bosch O, Salas A, Benitez D
    Abstract
    Present therapy of inflammatory bowel diseases (IBD) is aimed at relieving inflammation and treating signs and symptoms. Despite an optimized use of immunosuppressors and the new biologic agents, the need for intestinal resection in Crohn's disease (CD)has remained stable.1[1] Primary and secondary failure to respond to approved therapies, and in some cases inability to provide a surgical solution to a particular patient due to extension and/or location of lesions, represent unmet needs in the treatment of IBD. Two streams of research, experimental and clinical, are the origin of the increasing utilization of cell therapies for severe immune-mediated diseases including IBD, these include stem cell therapies, and select...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362571</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362571</guid>        </item>
        <item>
            <title>What is the optimal treatment for anemia in inflammatory bowel disease?</title>
            <link>http://www.medworm.com/index.php?rid=5362570&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023204%26dopt%3DAbstract</link>
            <description>This article discusses the underlying physiology of anemia in IBD, and presents the current evidence supporting treatment options available.
    PMID: 22023204 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362570</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362570</guid>        </item>
        <item>
            <title>Feasibility of Assam Bora rice starch as a Compression coat of 5-fluorouracil core tablet for colorectal cancer.</title>
            <link>http://www.medworm.com/index.php?rid=5362569&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023205%26dopt%3DAbstract</link>
            <description>Authors: Ahmad MZ, Akhter S, Anwar M, Singh A, Ahmad I, Ain R, Jain GK, Khar RK, Ahmad FJ
    Abstract
    The colon and rectum are the parts of digestive system of human beings. Cancer affecting either of these organs may be called colorectal cancers. Conventional cancer chemotherapy is not very effective for treatment of colorectal cancer, as the drug molecule does not reach the target site at therapeutic concentration, on the other side they produces sever systemic toxic effect. Aim of this study was to develop a novel colon targeted Assam Bora rice starch compression coated tablet for site specific delivery of 5-FU to the colon without the drug being released in stomach or small intestine. Core tablet of 5-FU was prepared using microcrystalline cellulose (MCC) and spray dried lactose b...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362569</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362569</guid>        </item>
        <item>
            <title>Floating microspheres - To prolong the gastric retention time in stomach.</title>
            <link>http://www.medworm.com/index.php?rid=5362568&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023206%26dopt%3DAbstract</link>
            <description>Authors: Bhadouriya P, Kumar M, Pathak K
    Abstract
    A gastroretentive drug delivery system with prolong retention time in the stomach have great practical importance for drugs with an absorption window in the upper small intestine. Floating drug delivery system are expected to remain buoyant in the gastric content for prolong duration of time thus enhance the bioavailability of drugs. There are several gastroretentive drug delivery systems, which are floating microspheres, granules, tablets, powder, pills, laminated films and capsules. Floating microspheres are gaining special attention because of their wide applicability in the targeting of drug to stomach. Floating microspheres have several advantages, that they remain buoyant in the stomach and distributed uniformly to avoid the v...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362568</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362568</guid>        </item>
        <item>
            <title>Dual Controlled Release, In Situ Gelling Periodontal Sol Of Metronidazole Benzoate And Serratiopeptidase: Statistical Optimization And Mechanistic Evaluation.</title>
            <link>http://www.medworm.com/index.php?rid=5362567&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023207%26dopt%3DAbstract</link>
            <description>Authors: Kumari N, Pathak K
    Abstract
    In situ gelling syringeable periodontal sol capable of dual controlled delivery of metronidazole benzoate and serratiopeptidase were designed based on 23 factorial design with drug, poloxamer 407 and aerosil as independent variables and sol gel transition characteristics, %CDR48h and palatability as responses. The sols had agreeable taste, were mucoadhesive, syringeable and inverted into gels at periodontal cavity temperature. F8 with optimal drug release was identified as the best formulation. The dispersion characteristics of poloxamer significantly affected the pharmacotechnical properties of the in situ gelling systems. Extra design checkpoint generated using Design Expert software 8.02 (Stat-Ease, USA) validated the experimental design. Thu...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362567</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362567</guid>        </item>
        <item>
            <title>Novel Penetration Enhancers for Skin Applications: A Review.</title>
            <link>http://www.medworm.com/index.php?rid=5362566&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023208%26dopt%3DAbstract</link>
            <description>Authors: Parhi R, Mondal S, Kumar PM
    Abstract
    The use of topical formulation is popular over the past decade due to extensive researches have been made in the field of transedermal drug delivery. As a result an increasing number of drugs are being added to the list of therapeutic agents that can be delivered to systemic circulation through the skin. Commonly available dosage forms for the topical application are creams, ointments, gels, patches etc. The therapeutic benefits of the above topical formulations are limited due to barrier property of stratum corneum (SC). The use of chemical penetration enhancers (CPEs) is one of the long standing approach to overcome the barrier property of SC. Numerous class of novel compounds have been evaluated for penetration enhancement activity, ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362566</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362566</guid>        </item>
        <item>
            <title>Preparation and characterization of poly(2-hydroxyethyl methacrylateco- methyl methacrylate) hydrogels for sustained delivery of antitumor drug.</title>
            <link>http://www.medworm.com/index.php?rid=5362565&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023209%26dopt%3DAbstract</link>
            <description>Authors: Babu D M, C S S, Shah AP, H G S
    Abstract
    The aim of this study was to prepare different types of cisplatin loaded poly(HEMA-co-MMA) hydrogel based implants. These systems are designed to release the drug in a time-controlled manner over several weeks which can help in optimizing the treatment of tumors. The prepared implants were evaluated for swellability, in vitro and in vivo release and biodegradation studies. Swelling studies of the implants were carried out in 7.4 pH phosphate buffer solution and swelling was to depend on the extent of cross-linking. From the results of in vitro release studies it was observed that, the diffusion coefficient of cisplatin in the early stages was in the range of 4.3× 10-6 to 8.0 ×10-6 cm2 min-1 and at later stages it was found to be i...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362565</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362565</guid>        </item>
        <item>
            <title>Preparation and Characterization of Spray-dried Mucoadhesive Microspheres of Ketorolac for Nasal Administration.</title>
            <link>http://www.medworm.com/index.php?rid=5362564&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023210%26dopt%3DAbstract</link>
            <description>In conclusion, spray dried microspheres based on chitosan could be suitable nasal delivery system for the administration of ketorolac.
    PMID: 22023210 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362564</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362564</guid>        </item>
        <item>
            <title>Natural Oils as Skin Permeation Enhancers for Transdermal Delivery of Olanzapine: In vitro and In vivo Evaluation.</title>
            <link>http://www.medworm.com/index.php?rid=5362563&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023211%26dopt%3DAbstract</link>
            <description>Authors: Aggarwal G, Dhawan S, Harikumar SL
    Abstract
    The feasibility of development of transdermal delivery system of olanzapine utilizing natural oils as permeation enhancers was investigated. Penetration enhancing potential of corn (maize) oil, groundnut oil and jojoba oil on in vitro permeation of olanzapine across rat skin was studied. The magnitude of flux enhancement factor with corn oil, groundnut oil and jojoba oil was 7.06, 5.31 and 1.9 respectively at 5mg/ml concentration in solvent system. On the basis of in vitro permeation studies, eudragit based matrix type transdermal patches of olanzapine were fabricated using optimized concentrations of natural oils as permeation enhancers. All transdermal patches were found to be uniform with respect to physical characteristics. T...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362563</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362563</guid>        </item>
        <item>
            <title>Natural Killer cells preferentially target cancer stem cells; Role of monocytes in protection against NK cell mediated lysis of cancer stem cells.</title>
            <link>http://www.medworm.com/index.php?rid=5362562&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023212%26dopt%3DAbstract</link>
            <description>Authors: Jewett A, Tseng HC, Arasteh A, Saddat S, Christensen RE, Cacalano NA
    Abstract
    Mounting effective anti-tumor immune responses by cytotoxic effectors is important for the clearance of tumors. However, accumulated evidence suggests that the cytotoxic function of immune effectors is largely suppressed in the tumor microenvironment by a number of distinct effectors and their secreted factors. The aims of this review are to provide a rationale and potential mechanism for immunosuppression in cancer, and to demonstrate the significance of such immunosuppression in cellular differentiation and tissue regeneration in pathological conditions, and progression of cancer. We have recently shown that increased NK cell function was seen when they were cultured with primary oral squamous ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362562</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362562</guid>        </item>
        <item>
            <title>Molecular Targeted Therapy In Melanoma: A Way To Reverse Resistance To Conventional Drugs.</title>
            <link>http://www.medworm.com/index.php?rid=5362561&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023213%26dopt%3DAbstract</link>
            <description>Authors: Maira F, Catania A, Candido S, Russo AE, McCubrey JA, Libra M, Malaponte G, Fenga C
    Abstract
    Cutaneous melanoma is the most aggressive skin cancer. Beside surgery, it is treated with chemotherapy and immunotherapy. However, many patients relapse after adjuvant therapy. The recent identification of several key molecular pathways implicated in the pathogenesis of melanoma is spreading development of a number of new translational targeted therapies which could play an important role in overcoming or minimizing resistance to chemotherapeutic drugs and proapoptotic therapies. This review summarizes environmental factors and the most significant molecular events involved in melanoma pathogenesis, disclosing mechanisms responsible for drug resistance and pointing out the clinical...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362561</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362561</guid>        </item>
        <item>
            <title>Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL).</title>
            <link>http://www.medworm.com/index.php?rid=5362560&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023214%26dopt%3DAbstract</link>
            <description>Authors: Masood A, Shahshahan MA, Jazirehi AR
    Abstract
    Chronic lymphocytic leukemia (CLL) is an archetype of malignancy resulting from defects in apoptosis. CLL is an exclusive accumulative disorder marked by low proliferative activity and gradual accumulation of clonal B-lymphocytes blocked in the early (G0, G1) phases of the cell cycle. The heterogeneous clinical course indicates diverse in vivo biology of the leukemic cell and suggests that CLL represents diverse behavior. Understanding the molecular biology of the disease has provided insight into the mechanisms that promote tumorigenesis, specifically defective apoptotic signaling pathways. In this review we attempt to provide a comprehensive discussion of CLL including the origin of malignant lymphocytes, the apoptotic defect...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362560</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362560</guid>        </item>
        <item>
            <title>Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castleman's Disease.</title>
            <link>http://www.medworm.com/index.php?rid=5362559&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023215%26dopt%3DAbstract</link>
            <description>Authors: Reid E, Nooka A, Blackmon J, Lechowicz MJ
    Abstract
    The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDS-related non-Hodgkin lymphoma and Multicentric Castleman's disease.
    PMID: 22023215 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5362559</comments>
            <pubDate>Fri, 21 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5362559</guid>        </item>
        <item>
            <title>Development of novel drug delivery prototypes devices for targeted delivery drug therapy at the molecular level in aqueous media.</title>
            <link>http://www.medworm.com/index.php?rid=5142561&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21843149%26dopt%3DAbstract</link>
            <description>Authors: George R, Oberhozer T, Perchyonok VT
    Abstract
    A novel approach in target specific molecular prototype drug delivery system concerns the attempt to employ radical affording substances (RAS) or radical quenching substances (RQS) as prodrugs able to produce irreversible damage on the desired target and therefore to stimulate cellular apoptosis. However, radical species generated can react quickly within the chemical environment prior to reaching its proper site of action. In this short communication, we report our investigations towards developing two alternative novel, simple, flexible and effective drug delivery systems that provide optimal dosage of drugs precisely where and when needed and therefore achieve and sustain a complex delivery profile. We have demonstrated the ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5142561</comments>
            <pubDate>Sat, 20 Aug 2011 09:24:12 +0100</pubDate>
            <guid isPermaLink="false">5142561</guid>        </item>
        <item>
            <title>Chronotherapeutic Drug Delivery Systems - An Approach to Circardian Rhythms Diseases.</title>
            <link>http://www.medworm.com/index.php?rid=5142562&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21831038%26dopt%3DAbstract</link>
            <description>Authors: Sunil SA, Srikanth MV, Rao NS, Uhumwangho MU, Latha K, Murthy KV
    Abstract
    The purpose of writing this review on chronotherapeutic drug delivery systems (ChrDDs) is to review the literatures with special focus on ChrDDs and the various dosage forms, techniques that are used to target the circadian rhythms (CR) of various diseases. Many functions of the human body vary considerably in a day. ChrDDs refers to a treatment method in which in vivo drug availability is timed to match circardian rhythms of disease in order to optimize therapeutic outcomes and minimize side effects. Several techniques have been developed but not many dosage forms for all the diseases are available in the market. ChrDDs are gaining importance in the field of pharmaceutical technology as these system...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5142562</comments>
            <pubDate>Mon, 08 Aug 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5142562</guid>        </item>
        <item>
            <title>Nanodrug Delivery Systems in Dentistry: A Review on Current Status and Future Perspectives.</title>
            <link>http://www.medworm.com/index.php?rid=4969192&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696348%26dopt%3DAbstract</link>
            <description>Authors: Renugalakshmi A, Vinothkumar TS, Kandaswamy D
    The present review provides an insight into various potential areas of dentistry that are being invaded by nanotechnology based drugs and drug delivery systems. Current treatments for diseases of dental and oral structures rely on the use of classical pharmacological agents which, in some cases are limited by low efficacy and lack of selectivity to target cells. However, various nanostructures in drug delivery and their challenges in the field of dentistry have not been reviewed so far in the literature. The different treatment opportunities of importance include caries control restorations, tooth remineralisation, management of dentinal hypersensitivity, dental caries vaccine, management of oral biofilm, root canal disinfection, l...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969192</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969192</guid>        </item>
        <item>
            <title>Development of Polysaccharide Based Colon Targeted Drug Delivery System: Design and Evaluation of Assam Bora Rice Starch Based Matrix Tablet.</title>
            <link>http://www.medworm.com/index.php?rid=4969191&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696349%26dopt%3DAbstract</link>
            <description>Authors: Ahmad MZ, Akhter S, Rahman M, Ahmad I, Anwar M, Jain GK, Ahmad FJ, Khar RK
    The aim of this study was to develop a novel colon targeted matrix tablet containing Metronidazole (MTZ) as model drug. Matrix tablets were prepared using Assam Bora rice starch, which is essentially a natural polymer, by wet granulation technique. The granules prepared were subjected to evaluation for angle of repose, bulk density, compressibility index, Hausner's ratio, total porosity, and drug content. The developed tablets were also analysed for thickness, diameter, weight variation tests, tablet crushing strength, friability, and in vitro release studies. The granules displayed satisfactory flow properties, compressibility, Hausner's ratio and drug content. Almost all the tablet formulations showed...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969191</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969191</guid>        </item>
        <item>
            <title>Local Delivery of Therapeutics for Percutaneous Coronary Intervention.</title>
            <link>http://www.medworm.com/index.php?rid=4969190&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696350%26dopt%3DAbstract</link>
            <description>Authors: Kennedy KL, Lucas AR, Wan W
    Percutaneous coronary intervention (PCI) has become a highly effective alternative for the treatment of coronary artery disease. The use of stents has reduced the rates of restenosis by preventing elastic recoil and negative remodeling, however neointima formation still remains an issue. Local drug delivery is an attractive option to maintain effective drug concentrations at the site of arterial injury without risking systemic toxicity. Drug-eluting stents (DESs) are implanted to provide local drug delivery to combat neointima formation by slowing cell proliferation and migration. However, problems still remain with DES use including the non-specificity of therapeutics, incomplete endothelialization leading to late thrombosis, necessity for longer t...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969190</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969190</guid>        </item>
        <item>
            <title>Evidence for Extensive Non-Endocytotic Translocation of Peptide Nucleic Acids Across Mammalian Plasma Membranes.</title>
            <link>http://www.medworm.com/index.php?rid=4969189&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696351%26dopt%3DAbstract</link>
            <description>Authors: Oehlke J, Turner Y, Pritz S, Bienert M
    The ability of peptide nucleic acids (PNA) to enter and to cross filter-grown MDCK, HEK and CHO cells was studied by means of a protocol based on capillary electrophoresis combined with laser-induced fluorescence detection. The used approach avoided possible errors encountered in protocols based on confocal laserscanning microscopy and FACS analysis. In contradiction to the commonly anticipated unability of PNA to cross biomembranes, extensive translocation of unmodified PNA into and across the investigated cell types was found. The transport mode comprised a variety of energy dependent and -independent as well as temperature sensitive mechanisms being probably destined to natural substrates and hijacked by PNA. The presented results sugg...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969189</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969189</guid>        </item>
        <item>
            <title>In vitro and In vivo Characterization of Novel Biomaterial for Transdermal Application.</title>
            <link>http://www.medworm.com/index.php?rid=4969188&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696352%26dopt%3DAbstract</link>
            <description>Authors: Mundada AS, Avari JG
    Polymers have become an indispensable part in the design of a conventional as well as novel drug delivery system. Gum Copal (GC), a novel biomaterial obtained from Agathis species, is evaluated in the present study for its potential application as a matrix former in transdermal drug delivery systems. GC was initially characterized for various physicochemical properties and then mechanical characterization of the Plasticized films of GC was investigated. Verapamil hydrochloride (VH), owing to its pharmacokinetic properties, was selected as the model drug for the present work. Matrix type transdermal films of VH with GC, alone and in combination with polyvinyl pyrrolidone (PVP K-30), were developed and evaluated for various physicochemical properties. In-vit...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969188</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969188</guid>        </item>
        <item>
            <title>Quick-Release Bromocriptine for Treatment of Type 2 Diabetes.</title>
            <link>http://www.medworm.com/index.php?rid=4969187&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696353%26dopt%3DAbstract</link>
            <description>Authors: Mikhail N
    Quick-release bromocriptine (bromocriptine-QR) (Cycloset) was approved in 2009 for treatment of type 2 diabetes. The exact anti-diabetic mechanism of action of bromocriptine-QR has not been elucidated, but the drug may help resetting the circadian dopamine signal. Randomized placebo-controlled trials showed that the mean reduction in hemoglobin A1c (HbA1c) levels by bromocriptine-QR was 0.0-0.2% when compared to baseline and 0.4-0.5% when compared with placebo after 24 weeks of therapy. Withdrawal rates due to adverse effects in patients receiving bromocriptine-QR and placebo were 24% and 11%, respectively. The most common adverse effect of bromocriptine-QR was nausea reported by 32% of patients compared with 7% of patients randomized to placebo. The advantages of br...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969187</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969187</guid>        </item>
        <item>
            <title>Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review.</title>
            <link>http://www.medworm.com/index.php?rid=4969186&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696354%26dopt%3DAbstract</link>
            <description>Authors: Sathish D, Kumar YS, Shayeda , Rao YM
    Oral delivery of the drug is the most preferable route of drug delivery due to the ease of administration, patient compliance and flexibility in the formulations. Recent technological advancements have been made in controlled oral drug delivery systems by overcoming physiological difficulties, such as short gastric residence time and highly variable gastric emptying time. Gastroretentive dosage forms have been designed over the past three decades to overcome these difficulties. Several technical approaches are currently utilized in the prolongation of gastric residence time, including highdensity, swelling and expanding, polymeric mucoadhesive, ion-exchange, raft forming, magnetic and floating drug delivery systems (FDDS), as well as other...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969186</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969186</guid>        </item>
        <item>
            <title>Depot Based Drug Delivery System for the Management of Depression - A Review.</title>
            <link>http://www.medworm.com/index.php?rid=4969185&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696355%26dopt%3DAbstract</link>
            <description>Authors: Pilaniya U, Khatri K, Patil UK
    Depression is a common mental disorder discerns with depressed mood, loss of interest, the primary treatment methods are drug therapy, electroconvulsive therapy, psychotherapy, light therapy, vagus nerve stimulation, etc. A number of innovative delivery systems have been developed to address suboptimal therapy outcomes by enhancing drug delivery, assuring efficacy of treatment, reducing side effects, improving compliance and drug targeting specific locations resulting in a higher efficiency. Depot delivery offers the advantage of a very high loading, controlled release of drug for an extended period of time and reduces frequency of dosing. The increase in AUC and decrease in Cmax reflects that the depot formulations could reduce the toxic complic...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969185</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969185</guid>        </item>
        <item>
            <title>Proposed Title: Enhanced Delivery of Topically-Applied Formulations following Skin Pre-Treatment with a Hand-applied, Plastic Microneedle Array.</title>
            <link>http://www.medworm.com/index.php?rid=4969184&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696356%26dopt%3DAbstract</link>
            <description>Authors: Duan D, Moeckly C, Gysbers J, Novak C, Prochnow G, Siebenaler K, Albers L, Hansen K
    The purpose of this work is to characterize microchannels created by polymeric microneedles, applied by hand, and to demonstrate enhanced delivery of topically applied formulations of lidocaine hydrochloride and methylprednisolone sodium succinate (MPSS). 3M's Microstructured Transdermal System (MTS) arrays were applied to domestic swine to demonstrate reliability of penetration, depth of penetration and durability of the structures to repeat application and high force. Tissue levels of lidocaine and MPSS following topical application with and without microneedle pretreatment were determined by HPLC-MS analysis following digestion of biopsies. Almost all microneedles penetrate the stratum corne...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969184</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969184</guid>        </item>
        <item>
            <title>Development of Novel Combined Time and pH-Dependent Based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon.</title>
            <link>http://www.medworm.com/index.php?rid=4969183&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696357%26dopt%3DAbstract</link>
            <description>Authors: Chickpetty SM, Baswaraj R, Sunil KG
    The present work is aimed to develop new oral drug delivery systems of 5-fluorouracil for the treatment of colorectal cancer by using hydrophilic swellable polymer hydroxy propyl methyl cellulose (HPMC) and pH responsive soluble polymer Eudragit L100 (ED) as coating materials. Core tablets containing 50mg of 5-fluorouracil were prepared by direct compression. The core tablets compression coated with different ratios (9:1, 8:2, 7:3, 6:4 and 5:5) of HPMC and ED with a coat weight of 300 and 400mg. All the formulations were evaluated for the hardness, friability, drug content uniformity and in vitro drug release studies in media of different pH 1.2, 7.4 and 6.8. The formulations released 0 to 7% of the drug in physiological environment of stoma...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969183</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969183</guid>        </item>
        <item>
            <title>Asymmetric Membrane Capsules of Phenylephrine Hydrochloride: An Osmotically Controlled Drug Delivery System.</title>
            <link>http://www.medworm.com/index.php?rid=4969182&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696358%26dopt%3DAbstract</link>
            <description>Authors: Kumar A, Philip AK, Pathak K
    The aim of the current study was to develop osmotically controlled release system of freely water soluble drug phenylephrine hydrochloride by use of asymmetric membrane capsules to reduce the dosing frequency and consequently improve the patient compliance. Ethyl cellulose asymmetric membrane capsules were developed by phase inversion process and solubility modulation was accomplished by common ion effect wherein sodium chloride was included in the formulation that also served as an osmogen. The effect of formulation variables namely level of polymer (ethyl cellulose), level of pore former (glycerol) and level of osmogen (sodium chloride) on the in vitro release of the drug was evaluated by 2(3) factorial design. Effects of environmental factors on...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969182</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969182</guid>        </item>
        <item>
            <title>Dark Chocolate and Blood Pressure: A Novel Study from Jordan.</title>
            <link>http://www.medworm.com/index.php?rid=4969179&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21696359%26dopt%3DAbstract</link>
            <description>Conclusion: Higher intake of dark chocolate can be associated with lower values of blood pressure, while its effect on heart rate values was not consistent.
    PMID: 21696359 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4969179</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4969179</guid>        </item>
        <item>
            <title>Advanced Techniques for Penetration Enhancement in Transdermal Drug Delivery System.</title>
            <link>http://www.medworm.com/index.php?rid=4719594&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453254%26dopt%3DAbstract</link>
            <description>Authors: Swain S, Beg S, Singh A, Patro CN, Rao ME
    Transdermal route has been recognized as a promising drug delivery system for systemic delivery of drugs and provides the advantage of avoidance of first-pass effect, ease of use, better patient compliance, maintaining constant blood level for longer period of time and decrease side effects. The major pitfalls of this route lie with difficulty in permeation of drugs through the skin. Several literatures have been published for enhancing the permeation of drugs by chemical approaches. However the present review highlighted about the advanced physical techniques used for enhancing delivery of drugs such as structure-based, electrically based, velocity based and several other miscellaneous physical techniques for enhancing the permeation ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719594</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719594</guid>        </item>
        <item>
            <title>Mucoadhesive Patches of Salbutamol Sulphate for Unidirectional Buccal Drug Delivery: Development and Evaluation.</title>
            <link>http://www.medworm.com/index.php?rid=4719593&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453255%26dopt%3DAbstract</link>
            <description>Authors: Puratchikody A, Prasanth VV, Mathew ST, Kumar BA
    Mucoadhesive buccal patches of Salbutamol Sulphate were prepared using five different polymers (polyvinylpyrrolidone [PVP]), polyvinyl alcohol [PVA], water soluble chitosan [C(WS)], acid soluble chitosan [C(AS)], hydroxypropyl methyl cellulose [HPMC])in various proportions and combinations (C(WS)/PVP/HPMC, C(WS)/PVA/HPMC, C(AS)/PVP/HPMC, and C(AS)/PVA/HPMC). A3(2) full factorial design was used to design the experiments. A total of 72 patches were prepared. Thickness of the patches ranged between 0.3±0.003 and 0.6±0.009 mm. Mass of the patches were in the range of 68.12±4.6 to95.02±7.2mg. Patches showed increased mass whenever PEG -400 was used as plasticizer. The surface pH of patches were acidic to neutral (pH 4-pH 7). Pat...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719593</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719593</guid>        </item>
        <item>
            <title>Meloxicam Carbopol-Based Gels: Characterization and Evaluation.</title>
            <link>http://www.medworm.com/index.php?rid=4719592&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453256%26dopt%3DAbstract</link>
            <description>Authors: Sareen R, Kumar S, Gupta GD
    Purpose: To formulate and evaluate the hydrogels containing meloxicam for topical application and also compare the effect of penetration enhancers on release of drug. Methods: Meloxicam gels were prepared by dispersion method using carbopol-940 and 934 (1%w/w) as rate controlling polymer and drug penetration enhancers such as tween 80, oleic acid and sesame oil in the concentration of 1% and 2% . The formulated gels were evaluated for drug content, pH, viscosity, spreadability, extrudability, in vitro drug permeation, drug release kinetics, bioadhesion test, accelerated stability of selected gel formulation. The in vitro drug permeation through pig's skin was carried out by using Keshary-Chein diffusion cell and viscosity was determined by brookfiel...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719592</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719592</guid>        </item>
        <item>
            <title>Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review.</title>
            <link>http://www.medworm.com/index.php?rid=4719591&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453257%26dopt%3DAbstract</link>
            <description>Authors: Sathish D, Kumar YS, Rao YM
    Oral delivery of the drug is the most preferable route of drug delivery due to the ease of administration, patient compliance and flexibility in the formulations. Recent technological advancements have been made in controlled oral drug delivery systems by overcoming physiological difficulties, such as short gastric residence time and highly variable gastric emptying time. Gastroretentive dosage forms have been designed over the past three decades to overcome these difficulties. Several technical approaches are currently utilized in the prolongation of gastric residence time, including highdensity, swelling and expanding, polymeric mucoadhesive, ion-exchange, raft forming, magnetic and floating drug delivery systems (FDDS), as well as other delayed g...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719591</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719591</guid>        </item>
        <item>
            <title>Nanocrystal Technology in the Delivery of Poorly Soluble Drugs: An Overview.</title>
            <link>http://www.medworm.com/index.php?rid=4719590&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453258%26dopt%3DAbstract</link>
            <description>Authors: Nagarwal RC, Kumar R, Dhanawat M, Das N, Pandit JK
    Extensive attempts to overcome problems related to solubility of drugs for maximizing bioavailability at targeted sites in the body have been made. The issue of drug solubility appears to attract the continued interest of pharmaceutical manufacturers. In this context, nanocrystallization has emerged as an important tool. In the present review, the authors discuss the advantages of nanocrystallized drugs and examine the products available in the market as well as drugs in the pipeline using nanocrystal-based formulations, which are being developed by pharmaceutical companies for drug delivery.
    PMID: 21453258 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719590</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719590</guid>        </item>
        <item>
            <title>Meloxicam β-Cyclodextrin Transdermal Gel: Physicochemical Characterization and In Vitro Dissolution and Diffusion Studies.</title>
            <link>http://www.medworm.com/index.php?rid=4719589&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453259%26dopt%3DAbstract</link>
            <description>Authors: Abdul Rasool BK, Gareeb RH, Fahmy SA, Abdul Rasool AA
    The aim of the study was to develop a Meloxicam (ME) transdermal gel formulations based on complexation with β-cyclodextrin. ME β-Cyclodextrin gel formulations were prepared using four different gel bases with different concentrations and different permeation enhancers. The developed formulations were examined for their in vitro characteristics and their diffusion through a mouse skin. The gel formulations were prepared successfully. Physicochemical characterization of ME β-CD complex in solution state by phase solubility revealed 1:1 M complexation of ME with β-Cyclodextrin. ME release profiles from the inclusion complex were superior over ME alone. Hydroxypropyl methyl cellulose 15% w/w gel base was proven to be a sui...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719589</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719589</guid>        </item>
        <item>
            <title>Fast Dissolving Films: A Review.</title>
            <link>http://www.medworm.com/index.php?rid=4719588&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453260%26dopt%3DAbstract</link>
            <description>Authors: Chaturvedi A, Srivastava P, Yadav S, Bansal M, Garg G, Sharma PK
    Fast-dissolving drug delivery systems have been developed as an alternative to conventional dosage form as an oral means of drug delivery in case of chronic conditions. Now a day's fast dissolving films are preferred over conventional tablets and capsules for masking the taste of bitter drugs to increase the patient compliance. Fast dissolving films consist of a very thin oral strip which dissolves in less than one minute when placed on the tongue. Dissolvable oral thin films are in the market since past few years in the form of breath strips and are widely accepted by consumers for delivering vitamins, vaccines and other drug products. The various manufacturing techniques for the preparation of films have also b...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719588</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719588</guid>        </item>
        <item>
            <title>Use of Amino Acids as Counter Ions Improves the Solubility of the BCS II Model Drug, Indomethacin.</title>
            <link>http://www.medworm.com/index.php?rid=4719587&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453261%26dopt%3DAbstract</link>
            <description>This study aims to improve the drug solubility of a Biopharmaceutical Classification System class II (BCS II) model drug (Indomethacin; IND) using basic amino acids (L-arginine, L-lysine and L-histidine) as counterions. Three new salts were prepared using freeze drying method and characterised by FT-IR spectroscopy, proton nuclear magnetic resonance ((1)HNMR), Differential Scanning Calorimetry (DSC) and Thermogravimetric analysis (TGA). The effect of pH on IND solubility was also investigated using pH-solubility profile. Both arginine and lysine formed novel salts with IND, while histidine failed to dissociate the free acid and in turn no salt was formed. Arginine and lysine increased IND solubility by 10,000 and 2296 fold, respectively. An increase in dissolution rate was also observed fo...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719587</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719587</guid>        </item>
        <item>
            <title>Controlled Release of Plasmid DNA from Hyaluronan Nanoparticles.</title>
            <link>http://www.medworm.com/index.php?rid=4719586&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453262%26dopt%3DAbstract</link>
            <description>Authors: Mahor S, Collin E, Dash BC, Pandit A
    Encapsulation of plasmid DNA (pDNA) in nanoparticulate gene delivery systems offers the possibility of control in dosing, enhanced pDNA uptake, increased resistance to nuclease degradation and sustained release of functionally active pDNA over time. Extracellular matrix based biomaterial i.e. hyaluronan (HA) was used to encapsulate pDNA (pCMV-GLuc, Gaussia Luciferase reporter plasmid DNA having CMV promoter) in submicron size particulate system. Nano size range (˜400-600 nm) pDNA loaded hyaluronan nanoparticles were formulated by ionic gelation followed by the cross-linking method with high encapsulation efficiency (˜75-85%). The particle preparation process was further optimized for molecular weight, cross-linking method, cross-linking t...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719586</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719586</guid>        </item>
        <item>
            <title>Enhancement of Solubility and Permeability of Candesartan Cilexetil by Using Different Pharmaceutical Interventions.</title>
            <link>http://www.medworm.com/index.php?rid=4719585&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453263%26dopt%3DAbstract</link>
            <description>Authors: Shaikh SM, Avachat AM
    The poor solubility and wettability of Candesartan cilexetil (CAN) leads to poor dissolution and hence, low bioavailability after oral administration. The aim of the present study was to improve the solubility and dissolution rate and hence the permeability of CAN by preparing solid dispersions/inclusion complexes. Solid dispersions were prepared using PEG 6000 [hydrophilic polymer] and Gelucire 50/13 [amphiphilic surfactant] by melt agglomeration (MA) and solvent evaporation (SE) methods in different drug-to-carrier ratios, while inclusion complexes were made with hydroxypropyl-β-cyclodextrin (HP-β-CD) [complexing agent] by grinding and spray drying method. Saturation solubility method was used to evaluate the effect of various carriers on aqueous solu...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719585</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719585</guid>        </item>
        <item>
            <title>Oral Lipid Based Drug Delivery System (LBDDS): Formulation, Characterization and Application: A Review.</title>
            <link>http://www.medworm.com/index.php?rid=4719584&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453264%26dopt%3DAbstract</link>
            <description>Authors: Rahman MA, Harwansh R, Mirza MA, Hussain MS, Hussain A
    The major problem in oral drug formulations is low and erratic bioavailability, which mainly results from poor aqueous solubility. This may lead to high inter- and intra subject variability, lack of dose proportionality and therapeutic failure. The improvement of bio-availability of drugs with such properties presents one of the greatest challenges in drug formulations. Oral lipid based formulations are attracting considerable attention due to their capacity to increase the solubility, facilitating gastrointestinal absorption and reduce or eliminate the effect of food on the absorption of poorly water soluble, lipophilic drug and thus increasing the bioavailability. The present review outlines the recent findings on self-e...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719584</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719584</guid>        </item>
        <item>
            <title>Part I: Targeted Particles for Cancer Immunotherapy.</title>
            <link>http://www.medworm.com/index.php?rid=4719583&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21453265%26dopt%3DAbstract</link>
            <description>Authors: Hamdy S, Haddadi A, Hung RW, Ghobti Z, Lavasanifar A
    Dendritic cells (DCs) are the key antigen presenting cells that link innate and adoptive immunity. In the periphery, DCs capture antigens, process them and migrate into the regional lymph nodes where they could initiate antigen specific T cell immune responses. Immunotherapeutic strategies that aim to deliver tumor antigens specifically to DCs could not only boost anti-tumor immune responses but also could alleviate non-specific immune activation and/or unwanted side effects. Nano-sized particulate delivery systems are efficient modalities that can deliver tumor antigens to DCs in a targeted and specific manner. This review will provide general information on the rationale behind targeting antigens to DCs and the crucial rol...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4719583</comments>
            <pubDate>Thu, 31 Mar 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4719583</guid>        </item>
        <item>
            <title>Peptide-Based Subunit Nanovaccines.</title>
            <link>http://www.medworm.com/index.php?rid=4485476&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291373%26dopt%3DAbstract</link>
            <description>Authors: Skwarczynski M, Toth I
    Classical vaccines incorporating live or attenuated microorganisms possess several disadvantages and cannot be applied against cancer and some pathogens. Modern vaccines utilizing immunogenic subunits derived from a particular pathogen are able to overcome these obstacles but need a specific delivery system for their efficacy. Nanotechnology has opened a new window into these delivery methodologies. A nano-sized formulation of subunit vaccines has been proven to be very effective in inducing cellular and humoral immune responses. Here, we review a number of peptide vaccine delivery strategies based on nanoparticles composed of polymers, peptides, lipids, and inorganic materials.
    PMID: 21291373 [PubMed - as supplied by publisher] (Source: Current Drug...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485476</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485476</guid>        </item>
        <item>
            <title>Cancer, Signal Transduction and Nanotechnology.</title>
            <link>http://www.medworm.com/index.php?rid=4485475&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291374%26dopt%3DAbstract</link>
            <description>Authors: Sengupta P, Basu S, Sengupta S
    Understanding the mechanisms underlying different cellular signaling pathways implicated in the pathogenesis of cancer are leading to the identification of novel drug targets as well as novel drug candidates. Multiple targeted therapeutics that modulate aberrant molecular pathways have already reached the clinic. However, targeted therapeutics can exert mechanism-driven side effects as a result of the implication of the molecular target in normal physiological functions besides tumorigenesis. We hypothesize that targeted therapeutics can be optimized by merging them with nanotechnology, which offers the potential for preferential targeting to the tumor, resulting in increased intratumoral concentrations of the active agent with reduced distributi...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485475</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485475</guid>        </item>
        <item>
            <title>Targeted Particles for Imaging of Anticancer Immune Responses.</title>
            <link>http://www.medworm.com/index.php?rid=4485474&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291375%26dopt%3DAbstract</link>
            <description>Authors: Hung RW, Hamdy S, Haddadi A, Ghotbi Z, Lavasanifar A
    The interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential role of nanoscopic devices for molecular imaging of these immune responses. Nanoscopic devices could potentially deliver tracking molecules to DCs, enabling monitoring of DCs and/or T cell activation and tumoricidal activity during immunotherapy, using non-invasive imaging modalities such as nuclear imaging (singl...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485474</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485474</guid>        </item>
        <item>
            <title>Regulating Nanomedicine - Can the FDA Handle it?</title>
            <link>http://www.medworm.com/index.php?rid=4485473&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291376%26dopt%3DAbstract</link>
            <description>Authors: Bawa R
    There is enormous excitement and expectation surrounding the multidisciplinary field of nanomedicine - the application of nanotechnology to healthcare - which is already influencing the pharmaceutical industry. This is especially true in the design, formulation and delivery of therapeutics. Currently, nanomedicine is poised at a critical stage. However, regulatory guidance in this area is generally lacking and critically needed to provide clarity and legal certainty to manufacturers, policymakers, healthcare providers and the public. There are hundreds, if not thousands, of nanoproducts on the market for human use but little is known of their health risks, safety data and toxicity profiles. Less is known of nanoproducts that are released into the environment and that co...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485473</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485473</guid>        </item>
        <item>
            <title>Topical Delivery of Interferon alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections.</title>
            <link>http://www.medworm.com/index.php?rid=4485472&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291377%26dopt%3DAbstract</link>
            <description>Conclusions. Biphasic vesicles delivered clinically significant levels of IFN α across intact human skin and elicited marked therapeutic effect in patients.
    PMID: 21291377 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485472</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485472</guid>        </item>
        <item>
            <title>Nanomedicine: A New Frontier in Cancer Therapeutics.</title>
            <link>http://www.medworm.com/index.php?rid=4485471&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291378%26dopt%3DAbstract</link>
            <description>This article will attempt to describe some recent advances using nanoparticle drug delivery system in cancer therapy. The evolution history, the challenges and the role of nanoparticles in cancer drug delivery will briefly be discussed together with additional opportunities in cancer therapy. An overall understanding of these issues will help with further advancement of designing better drug delivery system that can be applied clinically.
    PMID: 21291378 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485471</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485471</guid>        </item>
        <item>
            <title>Amino Acid-Substituted Gemini Surfactant-Based Nanoparticles as Safe and Versatile Gene Delivery Agents.</title>
            <link>http://www.medworm.com/index.php?rid=4485470&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291379%26dopt%3DAbstract</link>
            <description>In this study, we evaluated the cytotoxicity of P/G/L nanoparticles and explored the relationship between transfection efficiency/toxicity and their physicochemical characteristics (such as size, binding properties, etc.). An overall low toxicity is observed for all complexes with no significant difference among substituted and unsubstituted compounds. An interesting result revealed by the dye exclusion assay suggests a more balanced protection of the DNA by the glycine and glycyl-lysine substituted compounds. Thus, the higher transfection efficiency is attributed to the greater biocompatibility and flexibility of the amino acid/peptide-substituted gemini surfactants and demonstrates the feasibility of using amino acid-substituted gemini surfactants as gene carriers for the treatment of di...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485470</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485470</guid>        </item>
        <item>
            <title>CH(50): A Revisited Hemolytic Complement Consumption Assay for Evaluation of Nanoparticles and Blood Plasma Protein Interaction.</title>
            <link>http://www.medworm.com/index.php?rid=4485469&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291380%26dopt%3DAbstract</link>
            <description>Authors: Meerasa A, Huang JG, Gu FX
    The use of nanoparticles as platforms or vehicles for applications in nanomedicine, such as drug delivery and medical imaging, has been widely reported in the literature. A key area of potential improvement in the development and implementation of nanoparticles is the design of surface treatments to maximize residence time in the bloodstream. Major obstacles to the prolonged circulation of nanoparticles include complement activation and opsonization, both of which contribute to the removal of foreign matter from the vasculature. A greater understanding of the mechanisms through which nanoparticles interact with the complement system of innate immunity may be necessary in future endeavours to optimize nanoparticle design. The range of experimental tec...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485469</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485469</guid>        </item>
        <item>
            <title>Non-Viral Nucleic Acid Delivery: Key Challenges and Future Directions.</title>
            <link>http://www.medworm.com/index.php?rid=4485468&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291381%26dopt%3DAbstract</link>
            <description>Authors: Elsabahy M, Nazarali A, Foldvari M
    Gene therapy holds the promise of correcting a genetic defect. It can be achieved with the introduction of a normal wild-type transgene into specific cells of the patient where the endogenous gene is underexpressing or by the introduction of a therapeutic agent, such as, antisense oligonucleotides (AON) or small interfering RNA (siRNA) to inhibit transcription and/or translation of an overexpressing endogenous gene or a cancer causing oncogene. Gene therapy has been utilized for vaccination and for the treatment of several diseases, such as, cancer, viral infections and dermatological diseases. However, there are many hurdles to overcome in developing effective gene-based therapeutics, including cellular barriers, enzymatic degradation and ra...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485468</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485468</guid>        </item>
        <item>
            <title>M Cells Prefer Archaeosomes: An In Vitro/In Vivo Snapshot upon Oral Gavage in Rats.</title>
            <link>http://www.medworm.com/index.php?rid=4485467&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291382%26dopt%3DAbstract</link>
            <description>Authors: Morilla MJ, Gomez DM, Cabral P, Cabrera M, Balter H, Tesoriero MV, Higa L, Roncaglia D, Romero EL
    The archaeolipids (lipids extracted from archaebacterias) are non saponificable molecules that form self sealed mono or bilayers (archaeosomes-ARC). Different to liposomes with bilayers made of conventional glycerophospholipids, the bilayer of ARC posses a higher structural resistance to physico chemical and enzymatic degradation and surface hydrophobicity. In this work we have compared the binding capacity of ARC exclusively made of archaeols containing a minor fraction of sulphoglycophospholipids, with that of liposomes in gel phase on M-like cells in vitro. The biodistribution of the radiopharmaceutical (99m)Tc-DTPA loaded in ARC vs that of liposomes upon oral administration to...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485467</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485467</guid>        </item>
        <item>
            <title>Nanotechnology Enables Superior Medical Therapies.</title>
            <link>http://www.medworm.com/index.php?rid=4485466&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21291383%26dopt%3DAbstract</link>
            <description>Authors: Foldvari M, Elsabahy M
    
    PMID: 21291383 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4485466</comments>
            <pubDate>Thu, 03 Feb 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4485466</guid>        </item>
        <item>
            <title>Polycaprolactone Fibres as a Potential Delivery System for Collagen to Support Bone Regeneration.</title>
            <link>http://www.medworm.com/index.php?rid=4418066&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235468%26dopt%3DAbstract</link>
            <description>Authors: McNeil SE, Griffiths HR, Perrie Y
    Poly(ε-caprolactone) (PCL) is biocompatible, non-immunogenic and non-toxic, and slowly degrades, allowing sufficient time for tissue regeneration. PCL has the potential for application in bone and cartilage repair as it may provide the essential structure required for bone regeneration, however, an ideal scaffold system is still undeveloped. PCL fibres were prepared using the gravity spinning technique, in which collagen was either incorporated into or coated onto the 'as-spun' fibres, in order to develop novel biodegradable polymer fibres which will effectively deliver collagen and support the attachment and proliferation of human osteoblast (HOB) cells for bone regeneration. The physical and mechanical characteristics and cell fibre interac...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418066</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418066</guid>        </item>
        <item>
            <title>Development and Evaluation of Stavudine Loaded Injectable Polymeric Particulate Systems.</title>
            <link>http://www.medworm.com/index.php?rid=4418065&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235469%26dopt%3DAbstract</link>
            <description>Authors: Sinha VR, Srivastava S
    Present research investigates the formulation of stavudine loaded biodegradable microspheres from different grades of Poly (D, L Lactide-co-glycolide) as a depot system for parenteral delivery. Prolonged release of stavudine facilitates reduction in symptoms of HIV infection and delay AIDS progression by reducing viral load to undetectable levels. Microspheres were prepared from PLGA 85:15 and PLGA 50:50 (RESOMER(®) 505H) by solvent evaporation technique with different drug/polymer ratios (1:4, 1:10, 1:20, 1:50, 1:100) and a polymer solution/vehicle ratio of 1:2. The effects of various formulation variables like polymer type and concentration, surfactant concentration and drug to polymer ratio on the characteristics of microspheres were evaluated. All t...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418065</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418065</guid>        </item>
        <item>
            <title>Direct Compression High Functionality Excipient using Coprocessing Technique: A Brief Review.</title>
            <link>http://www.medworm.com/index.php?rid=4418064&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235470%26dopt%3DAbstract</link>
            <description>Authors: Mirani AG, Patankar SP, Borole VS, Pawar AS, Kadam VJ
    Tablets are still the most commonly used dosage form because of the ease of manufacturing, convenience in administration, accurate dosing and excellent stability. Direct compression is the preferred method for the preparation of tablets. However, it has been estimated that less than 20 percent of the active pharmaceutical ingredients (API) can be processed into tablets via direct compression since the majority of API lack the flow, cohesion or lubricating properties required for direct compression. Increasing trends toward direct compression suggests the need for development of high functional excipients. High functionality of excipients can be obtained by development of new excipients or by particle engineering of existing...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418064</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418064</guid>        </item>
        <item>
            <title>Paclitaxel Loaded Nanosponges: In-vitro Characterization and Cytotoxicity Study on MCF-7 Cell Line Culture.</title>
            <link>http://www.medworm.com/index.php?rid=4418063&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235471%26dopt%3DAbstract</link>
            <description>Authors: Ansari KA, Torne SJ, Vavia PR, Trotta F, Cavalli R
    Beta cyclodextrin (β-CD) based nanosponges were synthesized and paclitaxel inclusion complex with nanosponges were prepared using techniques of inclusion complex formation. The paclitaxel nanosponge's complexes were evaluated for their release. The nanosponges complexes were also evaluated using DSC, FTIR, and NMR techniques for confirmation of inclusion complex formation between paclitaxel and nanosponges. Particle size and morphology of paclitaxel nanosponge's complex were estimated using SEM, TEM and dynamic light scattering techniques. The particle sizes were found out to be in range of 400 to 600 nm. Cytotoxic efficacy of paclitaxel nanosponge complex was determined against MCF-7 cells and paclitaxel nanosponge's complex...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418063</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418063</guid>        </item>
        <item>
            <title>Interactions Between Novel Terpenes and Main Components of Rat and Human Skin: Mechanistic View for Transdermal Delivery of Propranolol Hydrochloride.</title>
            <link>http://www.medworm.com/index.php?rid=4418062&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235472%26dopt%3DAbstract</link>
            <description>Authors: Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A
    The purpose of this study was to investigate the effectiveness and mechanism(s) of percutaneous absorption of propranolol hydrochloride (PHCL) across rat and human cadaver skin using seven novel terpenes with reference to marker terpene 1,8-cineole. In-vitro skin permeation studies were carried out via rat and human skin models. The mechanism of skin permeation of PHCL by terpenes was evaluated by FTIR, DSC, activation energy measurement and histopathological examination. Amongst the new terpenes, 1,4-cineole was found to be most effective enhancer for diffusion of PHCL through rat skin (ER=3.07) and human cadaver skin (ER=2.42) as compared to control. FTIR spectra and DSC thermogram of skin treated with aforesaid terpenes in...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418062</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418062</guid>        </item>
        <item>
            <title>Aerosol Delivery of Antimicrobial Agents During Mechanical Ventilation: Current Practice and Perspectives.</title>
            <link>http://www.medworm.com/index.php?rid=4418061&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235473%26dopt%3DAbstract</link>
            <description>Authors: Michalopoulos A, Metaxas EI, Falagas ME
    Critically ill patients, who develop ventilator-associated pneumonia during prolonged mechanical ventilation, often require antimicrobial agents administered through the endotracheal or the tracheotomy tube. The delivery of antibiotics via the respiratory tract has been established over the past years as an alternative route in order to deliver high concentrations of antimicrobial agents directly to the lungs and avoid systemic toxicity. Since the only formal indications for inhaled/aerosolized antimicrobial agents is for patients suffering from cystic fibrosis, consequently the majority of research and published studies concerns this group of patients. Newer devices and new antibiotic formulations are currently off-label used in ambulat...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418061</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418061</guid>        </item>
        <item>
            <title>Dynamics of Dissolution and Diffusion-Controlled Drug Release Systems.</title>
            <link>http://www.medworm.com/index.php?rid=4418060&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235474%26dopt%3DAbstract</link>
            <description>Authors: Simon L, Bolisetty P, Eraz MN
    Analytical expressions were derived to explain the influence of the dissolution/diffusion number (Di) on the time constant and steady-state flux when dispersed drugs are released from a finite matrix. A key novelty of this work is the introduction of a single time-constant that combined the analysis of both dissolution- and diffusion-based systems. Focus is placed on systems with a constant dissolution rate and diffusion coefficient. Solutions, based on the residue theorem, were in agreement with published results describing the transport of estradiol in a polymeric matrix. The experimental cumulative amount of drug released was 0.1 mg/cm2 in 100 hours compared to 0.084 mg/cm2 predicted by the theoretical model. The process time constant, estimate...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418060</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418060</guid>        </item>
        <item>
            <title>Formulation and Evaluation of Extended Release Asymmetric Membrane Capsules of Atenolol.</title>
            <link>http://www.medworm.com/index.php?rid=4418059&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235475%26dopt%3DAbstract</link>
            <description>The objective of this study was to demonstrate that the asymmetric membrane capsule can be used to deliver a poorly water soluble drug with a pH dependent solubility such as atenolol for extended periods of time by modulating solubility with organic acid. In osmotic systems, the release rate of an excipient relative to the release rate of the drug is an important factor that determines the duration of drug release. Consequently, for maintaining the desired pH over the entire period of drug dissolution a suitable thickening and suspending agent can be incorporated. By optimizing the concentration of thickening agent, it is possible to extend the availability of pH modifier in the core to provide an osmotic driving force or solubilization over the entire delivery period, so that the desired ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418059</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418059</guid>        </item>
        <item>
            <title>Newer Approaches for Optimal Bioavailability of Ocularly Delivered Drugs.</title>
            <link>http://www.medworm.com/index.php?rid=4418058&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235476%26dopt%3DAbstract</link>
            <description>Authors: Kesavan K, Balasubramaniam J, Kant S, Singh PN, Pandi JK
    Eye diseases can cause discomfort and anxiety in patients, with the ultimate fear of loss of vision and facial disfigurement. Many regions of the eye are relatively inaccessible to systemically administered drugs and, as a result, topical drug delivery remains the preferred route in most cases. Drugs may be delivered to treat the precorneal region for conjunctivitis and blepharitis, or to provide intraocular diseases such as glaucoma, uveitis, and cytomegalovirus retinitis. Most of the ophthalmic formulation strategies aim at maximizing ocular drug permeability through prolongation of the drug residence time in the cornea and conjunctival sac, as well as minimizing precorneal drug loss. The conventional topical ocular dr...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418058</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418058</guid>        </item>
        <item>
            <title>Assessment of Short-Term Changes Induced by a Dermatophagoides Pteronyssinus Extract on Asthmatic Patients. Randomised, Double-Blind, Placebo-Controlled Trial.</title>
            <link>http://www.medworm.com/index.php?rid=4418057&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235477%26dopt%3DAbstract</link>
            <description>Conclusion: After just 4 months of treatment, SCIT was capable of inducing in vivo and in vitro changes, but these changes were not reflected in improved clinical outcome within the first 4 months of therapy.
    PMID: 21235477 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418057</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418057</guid>        </item>
        <item>
            <title>Foam Preparations for the Treatment of Ulcerative Colitis.</title>
            <link>http://www.medworm.com/index.php?rid=4418056&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235478%26dopt%3DAbstract</link>
            <description>Authors: Loew BJ, Siegel CA
    Patients with ulcerative colitis uniformly have disease involving the distal colon. When patients have disease limited to the left colon or symptoms suggestive of active rectal inflammation, guidelines recommend topical rectal therapies as first-line agents either as monotherapy or in conjunction with oral products. Rectal delivery modalities offer the advantage of delivering high local concentrations of active medication to the site of maximal inflammation with minimization of systemic side effects. Methods of rectal administration include suppositories, liquid enemas and foams. Suppositories are limited to the treatment of rectal disease, and patients often have difficulty retaining the liquid enema secondary to its high volume and consistency. Rectal foam...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418056</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418056</guid>        </item>
        <item>
            <title>Characterization and In vitro Evaluation of Intestinal Absorption of Liposomes Encapsulating Zanamivir.</title>
            <link>http://www.medworm.com/index.php?rid=4418055&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235479%26dopt%3DAbstract</link>
            <description>Authors: Boonyapiwat B, Sarisuta N, Kunastitchai S
    Zanamivir is currently used for the treatment of H1N1 and H5N1 influenza viruses. Due to its highly hydrophilic property, zanamivir has poor oral bioavailability. Liposomal formulations are known to improve oral absorption of hydrophilic drugs. The present study investigates the effect of liposomes encapsulating zanamivir on the permeation of zanamivir across Caco-2 monolayers. Among the formulations studied, neutral liposomes composed of Phospholipon(®) 90 G and cholesterol at molar ratio of 7:3 gave the highest entrapment efficiency of zanamivir. The extrusion of liposomes loading zanamivir (LZV) resulted in the reduced-size liposomal zanamivir (RLZV), which had mean diameter at 283±42 nm and gave higher encapsulation efficiency of...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418055</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418055</guid>        </item>
        <item>
            <title>Microwave Assisted Synthesis and Evaluation of Modified Pea Starch as Tablet Superdisintegrant.</title>
            <link>http://www.medworm.com/index.php?rid=4418054&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235480%26dopt%3DAbstract</link>
            <description>Authors: Singh AV, Singh A, Nath LK
    In the present study, cross linked sodium carboxymethylated pea starch (SCPS) was synthesized and evaluated as tablet superdisintegrant in diclofenac sodium based tablets. SCPS was synthesized using native pea starch with monochloroacetic acid and NaOH in microwave radiation environment. Finally the dried product was cross-linked with phosphorous oxychloride, which produced granular highly swellable starch. SCPS with degree of substitution of 0.34 was formed and it was further evaluated as superdisintegrant in diclofenac sodium based tablets. Diclofenac sodium tablets were prepared by direct compression method with 2, 4, 6 and 8%w/w of SCPS as superdisintegrant and further comparatively evaluated for in vitro disintegration and dissolution study with...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418054</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418054</guid>        </item>
        <item>
            <title>Erythropoietin Encapsulation in Chitosan Nanoparticles and Kinetics of Drug Release.</title>
            <link>http://www.medworm.com/index.php?rid=4418053&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21235481%26dopt%3DAbstract</link>
            <description>Authors: Bokharaei M, Margaritis A, Xenocostas A, Freema DJ
    Recombinant human erythropoietin (rHu-EPO) is a glycoprotein, which is produced commercially from Chinese hamster ovary (CHO) cells. It is used for the therapy of renal anemia and chemotherapy-induced anemia in cancer patients. Recent evidence suggests that rHu-EPO exerts tissue protective effects via multiple mechanisms which include inhibition of apoptosis, promotion of angiogenesis and decreased inflammation. After intravenous (IV) injection, the blood concentration of rHu-EPO rapidly decreases due to proteolysis resulting in a relatively short half-life of 8.5 h, which necessitates regular dosing with intervals that do not exceed 7 days. It would be desirable to develop an encapsulated formulation providing controlled rele...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4418053</comments>
            <pubDate>Fri, 14 Jan 2011 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4418053</guid>        </item>
        <item>
            <title>Receptor-targeted cancer therapy.</title>
            <link>http://www.medworm.com/index.php?rid=4258667&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21138409%26dopt%3DAbstract</link>
            <description>Authors: Sun LC
    
    PMID: 21138409 [PubMed - in process] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4258667</comments>
            <pubDate>Wed, 15 Dec 2010 03:58:47 +0100</pubDate>
            <guid isPermaLink="false">4258667</guid>        </item>
        <item>
            <title>Endoglin-Targeted Cancer Therapy.</title>
            <link>http://www.medworm.com/index.php?rid=4140606&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034418%26dopt%3DAbstract</link>
            <description>Authors: Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y
    Vascular-targeting antiangiogenic therapy (VTAT) of cancer can be advantageous over conventional tumor cell targeted cancer therapy if an appropriate target is found. Our hypothesis is that endoglin (ENG; CD105) is an excellent target in VTAT. ENG is selectively expressed on vascular and lymphatic endothelium in tumors. This allows us to target both tumor-associated vasculature and lymphatic vessels to suppress tumor growth and metastasis. ENG is essential for angiogenesis/vascular development and a co-receptor of TGF-β. Our studies of selected anti-ENG monoclonal antibodies (mAbs) in several animal models and in vitro studies support our hypothesis. These mAbs and/o...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140606</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140606</guid>        </item>
        <item>
            <title>Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status.</title>
            <link>http://www.medworm.com/index.php?rid=4140605&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034419%26dopt%3DAbstract</link>
            <description>Authors: Sancho V, Di Florio A, Moody TW, Jensen RT
    The three mammalian bombesin (Bn) receptors (gastrin-releasing peptide [GRP] receptor, neuromedin B [NMB] receptor, BRS-3) are one of the classes of G protein-coupled receptors that are most frequently over-express/ectopically expressed by common, important malignancies. Because of the clinical success of somatostatin receptor-mediated imaging and cytotoxicity with neuroendocrine tumors, there is now increasing interest in pursuing a similar approach with Bn receptors. In the last few years then have been more than 200 studies in this area. In the present paper, the in vitro and in vivo results, as well as results of human studies from many of these studies are reviewed and the current state of Bn receptor-mediated imaging or cytotoxi...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140605</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140605</guid>        </item>
        <item>
            <title>Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy.</title>
            <link>http://www.medworm.com/index.php?rid=4140604&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034420%26dopt%3DAbstract</link>
            <description>Authors: Marik J, Junutula JR
    ImmunoPET is a non-invasive imaging technology based on tracking and quantification of radiolabeled monoclonal antibodies, antibody fragments and peptides in vivo. The knowledge of distribution and expression levels of a given receptor is a key for successful receptor targeted cancer therapy. ImmunoPET performed with probes with high affinity and specificity to a given receptor aspires to be a method for obtaining comprehensive information about current in vivo status of the targeted receptor. This review describes methods for radiolabeling of peptides, monoclonal antibodies, and antibody fragments for immunoPET and highlights the recently reported pre-clinical and clinical applications of immunoPET in receptor targeted therapy.
    PMID: 21034420 [PubMed ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140604</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140604</guid>        </item>
        <item>
            <title>Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes.</title>
            <link>http://www.medworm.com/index.php?rid=4140603&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034421%26dopt%3DAbstract</link>
            <description>Authors: Taratula O, Garbuzenko O, Savla R, Wang YA, He H, Minko T
    The ability of Superparamagnetic Iron Oxide (SPIO) nanoparticles and Poly(Propyleneimine) generation 5 dendrimers (PPI G5) to cooperatively provoke siRNA complexation was investigated in order to develop a targeted, multifunctional siRNA delivery system for cancer therapy. Poly(ethylene glycol) (PEG) coating and cancer specific targeting moiety (LHRH peptide) have been incorporated into SPIO-PPI G5-siRNA complexes to enhance serum stability and selective internalization by cancer cells. Such a modification of siRNA nanoparticles enhanced its internalization into cancer cells and increased the efficiency of targeted gene suppression in vitro. Moreover, the developed siRNA delivery system was capable of sufficiently enhan...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140603</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140603</guid>        </item>
        <item>
            <title>Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy.</title>
            <link>http://www.medworm.com/index.php?rid=4140602&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034422%26dopt%3DAbstract</link>
            <description>Authors: Mohanty C, Das M, Kanwar JR, Sahoo SK
    Receptor-mediated tumor targeting has received major attention in the field of cancer drug delivery in the past few years. Receptors, as molecular target has opened new opportunities for cellular or intracellular targeting of drug loaded delivery systems conjugated with targeting moieties i.e. ligand. This receptor mediated targeting of cancer drug through nano carrier sys¬tems to cancerous tissue offer protection and improves the pharmacokinetics of various drugs and help to overcome the systemic toxicity and adverse effects that result from the non-selective nature of most current cancer therapeutic agents. The article reviews the scope of receptor mediated targeting of anticancer drug loaded in various nanocarriers and also summarize r...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140602</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140602</guid>        </item>
        <item>
            <title>Radioimmunotherapy of Solid Tumors: Searching for the Right Target.</title>
            <link>http://www.medworm.com/index.php?rid=4140601&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034423%26dopt%3DAbstract</link>
            <description>Authors: Song H, Sgouros G
    Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The revie...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140601</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140601</guid>        </item>
        <item>
            <title>Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors.</title>
            <link>http://www.medworm.com/index.php?rid=4140600&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034424%26dopt%3DAbstract</link>
            <description>Authors: Schally AV, Engel JB, Emons G, Block NL, Pinski J
    Specific receptors for luteinizing hormone-releasing hormone (LH-RH), somatostatin, bombesin, and other peptides are found on various cancers. We review the development of cytotoxic analogs of LH-RH, somatostatin, and bombesin/gastrin releasing peptide (GRP) designed for targeting chemotherapy to peptide receptors on various cancers. Cytotoxic analogs of LH-RH, AN-152 and AN-207, containing doxorubicin (DOX) or 2-pyrrolino-DOX (AN-201), respectively, target LH-RH receptors and may be used for the treatment of prostatic and urinary bladder (urothelial), breast, ovarian and endometrial cancers, non-Hodgkin's lymphomas, melanomas, and renal cell carcinomas. DOX and AN-201 have also been incorporated into the cytotoxic analogs of s...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140600</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140600</guid>        </item>
        <item>
            <title>Somatostatin Receptor-targeted Anti-cancer Therapy.</title>
            <link>http://www.medworm.com/index.php?rid=4140599&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21034425%26dopt%3DAbstract</link>
            <description>Authors: Sun LC, Coy DH
    Somatostatin receptors (SSTRs), especially SSTR subtype 2, are found expressed at relatively higher levels in many tumor cells and in tumoral blood vessels relative to normal tissues. This creates an opportunity for developing various cytotoxic SST conjugates that selectively target SSTR2-specific sites. Accordingly, some potent chemotherapeutic agents such as camptothecin (CPT), methotrexate (MTX), paclitaxel (PTX) and doxorubicin (DOX) have been coupled to SSTR2-preferential somatostatin (SST) analogs. These new cytotoxic SST conjugates display significant SSTR-selective anti-tumor abilities in many different types of tumors. For instance, the CPT-SST conjugate JF-10-81, in which CPT is coupled to the N-terminus of a SSTR2-specific SST analog (JF-07-69), had w...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4140599</comments>
            <pubDate>Mon, 01 Nov 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4140599</guid>        </item>
        <item>
            <title>Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds.</title>
            <link>http://www.medworm.com/index.php?rid=4108939&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20973759%26dopt%3DAbstract</link>
            <description>Authors: Magolan J, Coster MJ
    The emerging &quot;anti-austerity&quot; anti-cancer therapeutic strategy targets the ability of certain cancer cell lines, particularly pancreatic cancer, to survive nutrient deprivation. While biochemical pathways for the tolerance to nutrient deprivation are still not well understood, a growing number of inhibitors of this process are being discovered. A number of natural products have been isolated, structurally characterized and evaluated as inhibitors of austerity, thereby providing valuable initial structure-activity relationship data.
    PMID: 20973759 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4108939</comments>
            <pubDate>Mon, 25 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4108939</guid>        </item>
        <item>
            <title>Drug Eluting Coronary Artery Stents.</title>
            <link>http://www.medworm.com/index.php?rid=4108938&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20973760%26dopt%3DAbstract</link>
            <description>Authors: Hirlekar R, Patel M, Jain S, Kadam V
    Atherosclerosis is the primary cause of coronary heart disease, which is characterized by a narrowing (stenosis) of the arteries that supply blood to tissues of the heart. Over the past decade, the use of &quot;Bare metallic stents&quot; during Percutaneous Transluminal Coronary Angioplasty (PTCA) has become a common practice for treating the coronary arterial stenosis. However, the restenosis is common problem in patients receiving stents. Recently, Drug-Eluting Stents (DES) with synthetic polymer coatings which act as drug reservoirs and elute drugs over a period of several weeks or months have emerged to tackle restenosis. The polymer coatings on these stents contain various drugs like immunosuppressive drugs, anti-neoplastic drugs, anti-inflammat...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4108938</comments>
            <pubDate>Mon, 25 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4108938</guid>        </item>
        <item>
            <title>Effect of Polyethylene Glycols on the Trans-Ungual Delivery of Terbinafine.</title>
            <link>http://www.medworm.com/index.php?rid=4098671&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20955143%26dopt%3DAbstract</link>
            <description>This study concluded that the low molecular weight PEGs are indeed a promising trans-ungual permeation enhancer.
    PMID: 20955143 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4098671</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4098671</guid>        </item>
        <item>
            <title>Combined Patch Containing Salicylic Acid and Nicotinamide: Role of Drug Interaction.</title>
            <link>http://www.medworm.com/index.php?rid=4082473&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950260%26dopt%3DAbstract</link>
            <description>Authors: Santi P
    The aim of the present study was to formulate a combined patch containing salicylic (SA) acid and nicotinamide (NA), useful for the treatment of mild acne, and to verify their mutual effect on drug permeation and skin retention. The performance of the patch was tested in vitro in permeation experiments using pig ear skin as barrier. To better understand the data obtained from the film, permeation from solutions and isopropyl myristate/water partition coefficient were also determined. The results obtained in the present work suggest a mutual influence of NA and SA on their permeation across the skin from an innovative transdermal film. The partition coefficient obtained when the two molecules were simultaneously present was typically lower than the respective value obta...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082473</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082473</guid>        </item>
        <item>
            <title>Evaluation of Assam Bora Rice Starch as Plasma Volume Expander by Polymer Analysis.</title>
            <link>http://www.medworm.com/index.php?rid=4082472&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950261%26dopt%3DAbstract</link>
            <description>Authors: Bhattacharya A, Akhter S, Shahnawaz S, Siddiqui W, Ahmad MZ
    Water soluble polysaccharides are currently finding increasing use as a basis material for plasma volume expander. In clinical setting it is desirable to have a precise knowledge of steric and chemical structure, since these affect the pharmacokinetics and pharmacology of plasma volume expander. Branch component of starch amylopectin is very similar in structure to glycogen, the reserve polysaccharide of animal and therefore is liable to be compatible with body tissue. The knowledge of weight average molecular mass, degree of branching, osmotic pressure and coil dimension are essential, since low molecular mass do not have desirable effect and large molar mass have undesirable effect. Assam Bora rice starch was charac...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082472</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082472</guid>        </item>
        <item>
            <title>Botulinum a Toxin Intravesical Injections for Painful Bladder Syndrome: Impact Upon Pain, Psychological Functioning and Quality of Life.</title>
            <link>http://www.medworm.com/index.php?rid=4082471&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950262%26dopt%3DAbstract</link>
            <description>Conclusion. In patients with refractory PBS with symptoms of anxiety, depression and poor QoL, BoNT/A intravesical treatment reduced bladder pain, improved psychological functioning, and well-being.
    PMID: 20950262 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082471</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082471</guid>        </item>
        <item>
            <title>Biodistribution Study Using Egg Protein ELISA Kit after Administration of FITC-labeled Ovalbumin Solution and Its Double Liposomes in the In Situ Loop Method, and Its Implication in Oral Immunization.</title>
            <link>http://www.medworm.com/index.php?rid=4082470&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950263%26dopt%3DAbstract</link>
            <description>In this study, an allergic substance-detecting kit, Egg Protein ELISA kit, was applied to the investigation of the biodistribution of fluorescein isothiocyanate-labeled ovalbumin (FITC-OVA). After FITC-OVA solution and its double liposomes were administered into the intestinal loop with one Peyer's patch, the biodistribution of FITC-OVA was examined with the Egg Protein ELISA kit. Each calibration was performed by fitting a quadratic curve to the observed ELISA response points. The ELISA response was almost the same between OVA and FITC-OVA. Similar ELISA response curves were obtained in Peyer's patch (PP) homogenate, spleen (SP) homogenate and plasma (PL). The concentration of FITC-OVA could be determined at 4 - 64 ng/ml for aqueous solution and SP homogenate and at 1 - 64 ng/ml for PP ho...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082470</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082470</guid>        </item>
        <item>
            <title>Drug Eluting Coronary Artery Stents.</title>
            <link>http://www.medworm.com/index.php?rid=4082469&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950264%26dopt%3DAbstract</link>
            <description>Authors: Hirlekar R, Patel M, Jain S, Kadam V
    Atherosclerosis is the primary cause of coronary heart disease, which is characterized by a narrowing (stenosis) of the arteries that supply blood to tissues of the heart. Over the past decade, the use of &quot;Bare metallic stents&quot; during Percutaneous Transluminal Coronary Angioplasty (PTCA) has become a common practice for treating the coronary arterial stenosis. However, the restenosis is common problem in patients receiving stents. Recently, Drug-Eluting Stents (DES) with synthetic polymer coatings which act as drug reservoirs and elute drugs over a period of several weeks or months have emerged to tackle restenosis. The polymer coatings on these stents contain various drugs like immunosuppressive drugs, anti-neoplastic drugs, anti-inflammat...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082469</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082469</guid>        </item>
        <item>
            <title>A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms.</title>
            <link>http://www.medworm.com/index.php?rid=4082468&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950265%26dopt%3DAbstract</link>
            <description>Authors: Sewlall S, Pillay V, Danckwerts MP, Choonara YE, Ndesendo VM, Lisa C
    Extensive research into circadian rhythms and their influence on biological systems has given rise to the science of chronobiology and subsequently chronotherapy, the science of delivering drugs in synchrony with biological rhythms. The field of chronotherapeutics paves the way for advances and complexities in current drug delivery technology. The ultimate goal of current chronopharmaceutical research strives to design ideal chronotherapeutic drug delivery systems that respond to such therapeutic needs. Considering the fact that physiological events such as heart rate, blood pressure, plasma concentration of hormones, plasma proteins and enzymes display constancy over time, drug delivery systems with constant...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082468</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082468</guid>        </item>
        <item>
            <title>Thermodynamics of Drug Nanoencapsulation: Case Study of Phenytoin-Poly (D, L-lactide) Nanocarrier.</title>
            <link>http://www.medworm.com/index.php?rid=4082467&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950266%26dopt%3DAbstract</link>
            <description>Authors: Vijay N, Murowchick JB, Youan BB
    In order to rationalize the nanoencapsulation process, a thermodynamic analysis allowed to predict the limit of a model drug (phenytoin, PHT) loading into poly (d, l-lactic acid) nanocarrier (PLA NC) prepared by solvent displacement method. The NC were characterized for size, morphology, thermal behavior and crystallography by dynamic light scattering, electron microscopies, differential scanning calorimetry, and powder X-ray diffraction, respectively. The drug loading, encapsulation efficiency (EE) and in vitro drug release profile were determined using high performance liquid chromatography. There was a logarithmic correlation between the partial molar free energy change based on the molecular descriptors and the drug / polymer weight (D/P) r...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082467</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082467</guid>        </item>
        <item>
            <title>Kinetics of Vascular Targeted Monoclonal Antibody.</title>
            <link>http://www.medworm.com/index.php?rid=4082466&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950267%26dopt%3DAbstract</link>
            <description>CONCLUSION: Accumulation of MAb targeted to epitopes in the vascular space occurs very rapidly, is highly specific and very efficient. Drug delivery with vascular targeting agents can accommodate fast acting therapeutic agents including short half lived radioisotopes.
    PMID: 20950267 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082466</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082466</guid>        </item>
        <item>
            <title>Local Delivery of Minocycline Hydrochloride: A Therapeutic Paradigm in Periodontal Diseases.</title>
            <link>http://www.medworm.com/index.php?rid=4082465&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950268%26dopt%3DAbstract</link>
            <description>Authors: Javed S, Kohli K
    From the literature we can draw conclusions regarding the local use of minocycline in periodontal diseases. This review article attempts to evaluate the role of local delivery of minocycline HCl in the management of periodontal diseases. The efficacies of several local delivery devices of minocycline like minocycline films, strips, gels/ointment, microspheres and nanoparticles are discussed. The functional characteristics of local delivery devices of minocycline, their effectiveness as monotherapy, and comparison with scaling and root planning (SRP) are discussed in detail. Methods for the analysis of minocycline in various biological fluids, clinical trials and patents relevant to the local use of minocycline HCl in dental diseases have also been addressed in...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082465</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082465</guid>        </item>
        <item>
            <title>Current Approaches for Drug Delivery to Central Nervous System.</title>
            <link>http://www.medworm.com/index.php?rid=4082464&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20950269%26dopt%3DAbstract</link>
            <description>Authors: Hossain S, Akaike T, Chowdhury EH
    Brain, the center of the nervous system in all vertebrate, plays the most vital role in every function of human body. However, many neurodegenerative diseases, cancer and infections of the brain become more prevalent as populations become older. In spite of the major advances in neuroscience, many potential therapeutics are still unable to reach the central nervous system (CNS) due to the blood-brain barrier (BBB) which is formed by the tight junctions within the capillary endothelium of the vertebrate brain. This results in the capillary wall behaving as a continuous lipid bilayer and preventing the passage of polar and lipid insoluble substances. Several approaches for delivering drugs to the CNS have been developed to enhance the capacity o...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4082464</comments>
            <pubDate>Thu, 14 Oct 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4082464</guid>        </item>
        <item>
            <title>Magnetically responsive Paclitaxel-loaded biodegradable nanoparticles for treatment of vascular disease: preparation, characterization and in vitro evaluation of anti-proliferative potential.</title>
            <link>http://www.medworm.com/index.php?rid=3858548&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695837%26dopt%3DAbstract</link>
            <description>Authors: Johnson B, Toland B, Chokshi R, Mochalin V, Koutzaki S, Polyak B
    Long term prevention of smooth muscle cell migration and proliferation inside the lumen of coronary arteries after stent implantation remains a challenge in medicine. Vascular stents have been coated with anti-proliferative drugs such as paclitaxel and rapamycin to improve the stents' efficacy. Maintaining adequate drug concentration on coronary stents presents an obstacle which magnetic nanoparticle (MNP) drug delivery could potentially overcome. Biodegradable, super-paramagnetic nanoparticles guided by high gradient magnetic fields have been proposed as transport vehicles for redosing stents with anti-proliferative drugs. The current study determined the characteristics of a number of candidate MNP formulations...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858548</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:34 +0100</pubDate>
            <guid isPermaLink="false">3858548</guid>        </item>
        <item>
            <title>Phosphodiesterase-5 inhibitor tadalafil acts on endothelial progenitor cells by CXCR4 signalling.</title>
            <link>http://www.medworm.com/index.php?rid=3858547&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695838%26dopt%3DAbstract</link>
            <description>Authors: Foresta C, De Toni L, Magagna S, Galan A, Garolla A
    It has been proposed that endothelial progenitor cells (EPC), originating from the bone marrow contribute to neo-angiogenesis in vivo by forming endothelial cells. Once released in the bloodstream, EPC home at the site of vascular damage where they participate in endothelium regeneration. In this process CXCR4 plays a key role. Recently we demonstrated that a prolonged therapy with phosphodiesterase-5 (PDE5) inhibitors does improve endothelial function and increases circulating EPC, suggesting a role of PDE5 in EPC physiology. Here we tested the expression of PDE5 and CXCR4 on cultured, circulating, and bone marrow resident EPC, and we studied the effect in vivo and in vitro of PDE5 inhibition after administration of a PDE5 i...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858547</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:31 +0100</pubDate>
            <guid isPermaLink="false">3858547</guid>        </item>
        <item>
            <title>Topical dermatological drug delivery: quo vadis?</title>
            <link>http://www.medworm.com/index.php?rid=3858546&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695839%26dopt%3DAbstract</link>
            <description>Authors: Akomeah FK
    Skin disease (dermatological conditions') affects at least one-third of the US population and has been cited as one of the top 15 medical conditions for which prevalence and healthcare spending increased in the last decade. The outcome of topical dermatological drug treatment is significantly influenced by the choice of vehicle or delivery system. Advancements in the life sciences coupled with a growing market for dermatologicals have facilitated the emergence of improved topical formulations and drug delivery systems. The current and emerging approaches of optimizing the topical delivery of dermatological agents (small and large molecules) include the use of chemical enhancers, bio-polymers (e.g. sodium hyaluronate), liposomes, particulate carriers (microspheres an...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858546</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:28 +0100</pubDate>
            <guid isPermaLink="false">3858546</guid>        </item>
        <item>
            <title>Release of antithrombotic drugs from alginate gel beads.</title>
            <link>http://www.medworm.com/index.php?rid=3858545&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695840%26dopt%3DAbstract</link>
            <description>Authors: JÃ¤mstorp E, Bodin A, Gatenholm P, Jeppsson A, StrÃ¸mme M
    The aim of the present work was to evaluate alginate hydrogels in the form of spherical beads as carrier for antithrombotic drugs for future use in artificial grafts. The ionotropic gelation technique was employed to prepare beads from the L. hyperborea stipe of alginate with two different alginate concentrations and two different guluronic to manuronic acid ratios. The beads were loaded, via soaking, with three different types of low molecular weight model molecules representing drugs with antithrombotic action and their release characteristics were subsequently evaluated. The entire release process of the negatively charged model drugs under study (Salicylic acid and Hirudin), was found to be governed by diffusion...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858545</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:25 +0100</pubDate>
            <guid isPermaLink="false">3858545</guid>        </item>
        <item>
            <title>Nanoparticles: a promising therapeutic approach in atherosclerosis.</title>
            <link>http://www.medworm.com/index.php?rid=3858544&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695841%26dopt%3DAbstract</link>
            <description>Authors: Antoniades C, Psarros C, Tousoulis D, Bakogiannis C, Shirodaria C, Stefanadis C
    Coronary atherosclerosis is the largest cause of mortality and morbidity in industrialised countries. Despite recent advances in medical therapies, the prevention and treatment of atherosclerosis remain suboptimal. Atherosclerosis is considered to be a chronic inflammatory disease of the arterial wall, involving the accumulation of macrophages and excess low density lipoproteins (LDL), the formation of foam cells which create the atheromatous plaque, resulting in stenosis, aneurysm and plaque rupture leading to acute coronary events. Every step in the atherogenesis process is a potential therapeutic target for both the prevention and regression of atherosclerosis. A novel approach is the use of nan...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858544</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:21 +0100</pubDate>
            <guid isPermaLink="false">3858544</guid>        </item>
        <item>
            <title>Chloroquine resistance: proposed mechanisms and countermeasures.</title>
            <link>http://www.medworm.com/index.php?rid=3858543&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695842%26dopt%3DAbstract</link>
            <description>Authors: Guantai E, Chibale K
    Malaria has been, and remains, one of the biggest global health concerns as far as infectious diseases are concerned, with yearly incidence and mortality figures running into millions. One of the major drawbacks to the control of this disease has been the emergence of drug resistant strains of the causative agent, which limits the successful use of many clinically available antimalarial drugs. This review discusses chloroquine resistance; it highlights some of the proposed molecular mechanisms of chloroquine resistance, but dwells more on efforts at reversing chloroquine resistance and the concept of chloroquine resistance-reversal agents.
    PMID: 20695842 [PubMed - in process] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858543</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:18 +0100</pubDate>
            <guid isPermaLink="false">3858543</guid>        </item>
        <item>
            <title>Evaluation of extemporaneously manufactured topical gels containing aceclofenac on inflammation and hyperalgesia in rats.</title>
            <link>http://www.medworm.com/index.php?rid=3858542&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695843%26dopt%3DAbstract</link>
            <description>Authors: Pabreja K, Dua K, Padi SS
    The systemic use of non-steroidal anti-inflammatory drugs (NSAIDs) which act by inhibiting cyclooxygenase (COX) is severely hampered by gastric and peptic ulcers. The topical delivery of NSAIDs has the advantages of avoiding gastric and peptic ulcers and delivering the drug to the inflammation site. Importance of aceclofenac as a new generational NSAID has inspired the development of topical dosage forms. This mode of administration may help to avoid typical side effects of NSAIDs associated with oral and systemic administration such as gastric irritation, particularly diarrhoea, nausea, abdominal pain and flatulence. The aim of this study was to formulate topical gel containing 1% of aceclofenac in carbopol and PEG base and to evaluate it for analges...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858542</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:14 +0100</pubDate>
            <guid isPermaLink="false">3858542</guid>        </item>
        <item>
            <title>Effect of iontophoresis and permeation enhancers on the permeation of an acyclovir gel.</title>
            <link>http://www.medworm.com/index.php?rid=3858541&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695844%26dopt%3DAbstract</link>
            <description>Authors: Vaghani SS, Gurjar M, Singh S, Sureja S, Koradia S, Jivani NP, Patel MM
    The purpose of the present study was to explore the combined effect of chemical enhancers and iontophoresis on the in vitro permeation of acyclovir gel across porcine skin. Acyclovir gel was formulated using carbopol 940 and hydroxypropyl methylcellulose K4M (HPMC K4M). Effect of drug concentration on the delivery of acyclovir was examined. Increasing drug concentration of acyclovir enhanced its flux across the skin. Incorporation of permeation enhancers (menthol, n-methyl-2-pyrrolidone and polyethylene glycol 400) into the gel resulted in enhanced acyclovir permeation when combined with iontophoresis. Menthol showed the highest drug permeation and when combined with iontophoresis it significantly increase...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858541</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:10 +0100</pubDate>
            <guid isPermaLink="false">3858541</guid>        </item>
        <item>
            <title>Utilization of hydrophilic swellable polymers as carriers for sustained drug delivery from matrices and three layer tablet systems.</title>
            <link>http://www.medworm.com/index.php?rid=3858540&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20695845%26dopt%3DAbstract</link>
            <description>Authors: Vlachou M, Naseef H, Efentakis M
    The purpose of this research was to develop and evaluate different sustained release preparations, using swellable polymers as carriers in the form of matrices and three-layer tablets. These preparations may offer a number of therapeutic advantages over immediate release dosage forms in drug delivery. The materials used for the fabrication of these systems were hydrophilic swellable polymers namely Metolose, Polyox, Xanthan gum and an erodible material Gantrez, acting as drug(diclofenac sodium) carriers. The powder characteristics determined for these polymers suggest good flowability with the exception of Gantrez. The addition of 1% of magnesium stearate resulted in improved flow properties for all polymers including Gantrez. Tablets were prep...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3858540</comments>
            <pubDate>Thu, 12 Aug 2010 13:48:07 +0100</pubDate>
            <guid isPermaLink="false">3858540</guid>        </item>
        <item>
            <title>Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity.</title>
            <link>http://www.medworm.com/index.php?rid=3610845&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20507267%26dopt%3DAbstract</link>
            <description>Authors: Kovacevic Z, Kalinowski DS, Lovejoy DB, Quach P, Wong J, Richardson DR
    Targeting essential nutrients (eg., those required for DNA synthesis) to inhibit cancer cell growth is a well established therapeutic strategy. A good example is the highly successful folate antagonist, methotrexate. However, up until recently, strategies to target iron which is also crucial for DNA synthesis have not been systematically explored to develop agents for the treatment of cancer. Over the last 15 years, our laboratory has embarked upon structure-activity studies designed to develop novel Fe chelators with anti-cancer efficacy. These studies have led to the development of the dipyridyl thiosemicarbazone chelators that show potent and selective anti-cancer activity and which overcome resistance t...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3610845</comments>
            <pubDate>Wed, 26 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3610845</guid>        </item>
        <item>
            <title>Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate.</title>
            <link>http://www.medworm.com/index.php?rid=3603176&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497099%26dopt%3DAbstract</link>
            <description>Authors: Singh KH, Shinde UA
    Micro and nanoparticulate carriers have been in focus in ophthalmic drug delivery with the objective of improving bioavailability, drug targeting and reducing pulse entry of the drug in ocular cul de sac. Polymeric nanoparticles for ocular purpose have potential in reducing the pulse entry and frequency of dosing, thus improving patient compliance. In the present study, mucoadhesive sodium alginate nanoparticles were developed for Brimonidine Tartrate (BT) as a model antiglaucoma drug by controlled ionic gelation technique. These nanoparticles would not only prolong drug's residence time but also reduce pulse entry in cul de sac. Nanoparticles were evaluated for morphology, surface characteristics, drug polymer interactions, particle size, polydispersibilit...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603176</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603176</guid>        </item>
        <item>
            <title>Design and Development of Thermoreversible Ophthalmic In Situ Hydrogel of Moxifloxacin HCl.</title>
            <link>http://www.medworm.com/index.php?rid=3603175&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497100%26dopt%3DAbstract</link>
            <description>Authors: Shastri DH, Prajapati ST, Patel LD
    Conventional eye drops show relatively low bioavailability due to poor precorneal contact time. In situ hydrogels are of great importance in providing sustained ocular drug delivery. By exhibiting elastic properties they resist ocular drainage of the drug leading to longer contact times. In the present study an in situ gelling thermoreversible mucoadhesive gel was formulated of an antibacterial agent, Moxifloxacin HCl using a combination of poloxamer 407 and poloxamer 188 with different mucoadhesive polymers such as Xanthan gum and Sodium alginate with a view to increase gel strength and bioadhesion force and thereby increased precorneal contact time and bioavailability of the drug. Formulations were evaluated for physical parameters like cla...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603175</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603175</guid>        </item>
        <item>
            <title>Phase Transited Asymmetric Membrane Capsule: A Means for Achieving Delayed and Controlled Osmotic Flow.</title>
            <link>http://www.medworm.com/index.php?rid=3603174&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497101%26dopt%3DAbstract</link>
            <description>Authors: Philip AK, Philip B
    In the present study, a phase transited nondisintegrating polymeric capsular system in achieving delayed as well as improved osmotic flow for the model drug cefadroxil was developed. Asymmetric membrane capsule (AMC) was prepared by precipitation of asymmetric membrane (AM) on the fabricated glass mold pins via wet phase inversion process. Effect of different formulation variables were studied based on 23 factorial design, namely, level of osmogen, ethylcellulose, pore former, apart from studying the effect of varying osmotic pressure on drug release. Scanning electron microscopy showed an outer dense non-porous region and an inner lighter porous region for the prepared AMC. Statistical test (Dunnett multiple comparison test) was applied for in vitro drug r...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603174</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603174</guid>        </item>
        <item>
            <title>Evaluation of the Combined Therapy of DA-7218, a New Oxazolidinone, and Trimethoprim/ Sulfamethoxazole in the Treatment of Experimental Actinomycetoma by Nocardia brasiliensis.</title>
            <link>http://www.medworm.com/index.php?rid=3603173&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497102%26dopt%3DAbstract</link>
            <description>Conclusions: In this work we proved that DA-7218 alone and combined with SXT is effective in the treatment of experimental actinomycetoma by Nocardia brasiliensis and that it could be potentially useful in the treatment of human actinomycetoma.
    PMID: 20497102 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603173</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603173</guid>        </item>
        <item>
            <title>Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges.</title>
            <link>http://www.medworm.com/index.php?rid=3603172&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497103%26dopt%3DAbstract</link>
            <description>Authors: Paul A, Elhayek E, Shum-Tim D, Prakash S
    Percutaneous transvascular coronary angioplasty and stenting is one of the most commonly employed interventional procedures for the treatment of occlusive coronary artery disease. The common long-term complication of this treatment is re-stenosis occuring at the site of the atherosclerotic lesion following stenting. The rate of re-stenosis within 6 months could be as high as 20-30% of patients resulting in increased morbidity and tremendous costs to the health care system. The incidence has been somewhat reduced with the development of drug eluting stents, releasing drugs like paclitaxel,sirolimus, zotarolimus and everolimus with varied sustained release profiles. However the long-term benefits from large studies are still controversial...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603172</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603172</guid>        </item>
        <item>
            <title>Characterization of Peptide Polymer Interactions in Poly(alkylcyanoacrylate) Nanoparticles: A Mass Spectrometric Approach.</title>
            <link>http://www.medworm.com/index.php?rid=3603171&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497104%26dopt%3DAbstract</link>
            <description>Authors: Kafka AP, Kleffmann T, Rades T, McDowell A
    Drug/polymer interactions occur during in situ polymerization of poly(alkylcyanoacrylate) (PACA) formulations. We have used MALDI ionization coupled tandem time-of-flight (TOF) mass spectrometry as an accurate method to characterize covalent peptide/polymer interactions of PACA nanoparticles with the bioactives D-Lys6-GnRH, insulin, [Asn1-Val5]-angiotensin II, and fragments of insulin-like growth factor 1 (IGF-1 (1-3)) and human adrenocorticotropic hormone (h-ACTH, (18-39)) at the molecular level. Covalent interactions of peptide with alkylcyanoacrylate were identified for D-Lys6-GnRH, [Asn1-Val5]-angiotensin II and IGF-1 (1-3). D-Lys6-GnRH and [Asn1-Val5]-angiotensin II were modified at their histidine side chain within the peptide, ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603171</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603171</guid>        </item>
        <item>
            <title>Ion Exchange Resins Transforming Drug Delivery Systems.</title>
            <link>http://www.medworm.com/index.php?rid=3603169&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497105%26dopt%3DAbstract</link>
            <description>Authors: Gupta S, Benien P, Sahoo PK
    Ion-exchange resins are light, porous, three-dimensional high molecular weight cross -linked matrix of hydrocarbon chains carrying positively or negatively charged sites that can attract an ion of opposite charge from the surrounding medium. There is stoichiometric exchange of mobile ions between the solid and the solution called as Ion-exchange which does not lead to any radical change in the properties and structure of the solid. Depending upon the type of Ionexchanged it can be either Cation-exchange or Anion-exchange. They are prepared in the form of granules, beads or sheets. As drug delivery systems they have received considerable attention after the 1950s due to their inertness, freedom from side effects, high drug loading capacity, ease of s...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603169</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603169</guid>        </item>
        <item>
            <title>Labeling of Fluorescent Probes to Albumin Microspheres and B16 Melanoma Extra-Cellular Antigen.</title>
            <link>http://www.medworm.com/index.php?rid=3603168&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20497106%26dopt%3DAbstract</link>
            <description>This study showed that the modified carbodiimide labeling method can serve as an alternative method for fluorescent labeling of target protein at reasonable cost particularly when sufficient amount of target protein is required for microsphere formulation screening.
    PMID: 20497106 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3603168</comments>
            <pubDate>Sun, 23 May 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">3603168</guid>        </item>
        <item>
            <title>Lipoplexes Formulation and Optimisation: In vitro Transfection Studies Reveal no Correlation with In vivo Vaccination Studies.</title>
            <link>http://www.medworm.com/index.php?rid=3288479&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158478%26dopt%3DAbstract</link>
            <description>Authors: McNeil SE, Vangala A, Bramwell VW, Hanson PJ, Perrie Y
    The aim of these studies was to compare the effect of liposome composition on physic-chemical characteristics and transfection efficacy of cationic liposomes both in vitro and in vivo. Comparison between 4 popularly used cationic lipids, showed 3b-N-(dimethylaminoethyl)carbamate (DC-Chol) to promote the highest transfect levels in cells in vitro with levels being at least 6 times higher than those of 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA). 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and dimethyldioctadecylammonium (DDA) and approximately twice as efficient as dipalmitoyl-trimethylammonium-propane (DPTAP). To establish the role of the helper lipid, DC-Chol liposomes were formulated in combination wit...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288479</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288479</guid>        </item>
        <item>
            <title>Ion Exchange Resins Transforming Drug Delivery Systems.</title>
            <link>http://www.medworm.com/index.php?rid=3288478&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158479%26dopt%3DAbstract</link>
            <description>Authors: Gupta S, Parul , Sahoo PK
    Ion-exchange resins are light, porous, three-dimensional high molecular weight cross -linked matrix of hydrocarbon chains carrying positively or negatively charged sites that can attract an ion of opposite charge from the surrounding medium. There is stoichiometric exchange of mobile ions between the solid and the solution called as Ion-exchange which does not lead to any radical change in the properties and structure of the solid. Depending upon the type of Ion-exchanged it can be either Cation-exchange or Anion-exchange. They are prepared in the form of granules, beads or sheets. As drug delivery systems they have received considerable attention after the 1950s due to their inertness, freedom from side effects, high drug loading capacity, ease of st...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288478</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288478</guid>        </item>
        <item>
            <title>Preparation and Evaluation of Isosorbide Mononitrate Hydrogels for Topical Fissure Treatment.</title>
            <link>http://www.medworm.com/index.php?rid=3288477&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158480%26dopt%3DAbstract</link>
            <description>Authors: Yoncheva K, Doytchinova I, Tankova L
    The aim of the present study was to prepare and evaluate hydrogels containing 0.1% isosorbide mononitrate (ISMN) for topical treatment of anal fissure. The hydrogels were prepared on the base of Carbopol 940, Poloxamer 407 or their combination. The highest viscosity and significant thyxotropy were observed for the combined hydrogel, which corresponded with slow drug release. Drug release from Poloxamer hydrogel was slow probably due to the heterogeneous structure of the gel - hydrophobic polyoxypropylene domains and hydrophilic polyoxyethylene domains. Drug release form Carbopol hydrogel was faster, which was associated with the lower viscosity and homogeneous gel structure. Further, Carbopol gel containing 0.1% ISMN (wt/wt) was tested on 2...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288477</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288477</guid>        </item>
        <item>
            <title>-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Reconstituted Human Oral Epithelium and Porcine Buccal Mucosa.</title>
            <link>http://www.medworm.com/index.php?rid=3288476&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158481%26dopt%3DAbstract</link>
            <description>In this study we would report the development of buccal tablets suitable for direct application of low-doses of 5-FU on cancer lesions. The topical administration could be effective on tumor area while systemic undesired side effects are avoided. Preliminarily, the limited tendency of 5-FU to cross the buccal tissue was established using reconstituted human oral epithelium (RHOE, in vitro) and porcine buccal mucosa (ex vivo) as mucosal models. The values of steady-state flux and permeability coefficient suggested the scarce aptitude of 5-FU to reach the systemic circulation. Matrix buccal tablets, were designed for 5-FU local delivery, developed and prepared. Release tests showed a highly reproducible Higuchian drug discharge. After tablet administration on buccal tissue specimens, the occ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288476</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288476</guid>        </item>
        <item>
            <title>Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti- Cancer Drugs: Current Status and Future Prospects.</title>
            <link>http://www.medworm.com/index.php?rid=3288475&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158482%26dopt%3DAbstract</link>
            <description>Authors: Utreja P, Jain S, Tiwary AK
    In the past years, alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. In conventional/current therapy oral tablet, capsule and injectable formulations are used for anti-cancer drugs delivery. These formulations associated with problems like severe toxic side effects on healthy organs, difficulties in clinical administration, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site specific controlled drug delivery systems. Novel drug delivery systems are capable of controlling the rate of drug delivery, sustaining the duration of therapeutic activity and targeting the drug to the disease tissue leading to better the...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288475</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288475</guid>        </item>
        <item>
            <title>Studies on Poloxamer Based Mucoadhesive Insitu Ophthalmic Hydrogel of Moxifloxacin HCL.</title>
            <link>http://www.medworm.com/index.php?rid=3288474&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158483%26dopt%3DAbstract</link>
            <description>Authors: Shastri DH, Prajapati ST, Patel LD
    Conventional eye drops shows relatively low bioavailability due to poor precorneal contact time. In situ hydrogels are of great importance in providing sustained ocular drug delivery due to their elastic properties hydrogels resist ocular drainage leading to longer contact times. In the present study an in situ gelling thermoreversible mucoadhesive gel was formulated of an antibacterial agent Moxifloxacin HCl using combination of poloxamer 407 and poloxamer 188 with different mucoadhesive polymers such as Xanthan gum and Sodium alginate with a view to increase in gel strength and bioadhesion force and thereby increase in precorneal contact time and there by increase in bioavailability of the drug. The formulations were evaluated for physical ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288474</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288474</guid>        </item>
        <item>
            <title>Synthetic Polyacrylate Polymers as Particulate Intranasal Vaccine Delivery Systems for the Induction of Mucosal Immune Response.</title>
            <link>http://www.medworm.com/index.php?rid=3288473&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158484%26dopt%3DAbstract</link>
            <description>Authors: Zaman M, Simerska P, Toth I
    The nasal route as a site of vaccine delivery for both local and systemic effect is currently of considerable interest. The administration of vaccines to mucosal surfaces such as the nasopharynx associated lymphoid tissues confers many advantages since the nasal mucosa is a primary site through which most inhaled antigens are encountered. However, the success of intranasally delivered mucosal vaccines is limited by lack of effective vaccine formulations or delivery systems suitable for use in humans. This review provides a brief overview of the mucosal immune system at the nasal surface, enhancement techniques for induction of mucosal immune response after intranasal administration of particulate systems and an explanation of the inherent properties...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288473</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288473</guid>        </item>
        <item>
            <title>Nanotechnology Andradiopharmaceuticals: Diagnostic and Therapeutic Approaches.</title>
            <link>http://www.medworm.com/index.php?rid=3288472&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158485%26dopt%3DAbstract</link>
            <description>Authors: Mironidou-Tzouveleki M, Tsartsalis S
    Nanotechnology is a novel but rapidly advancing domain of Therapeutics. Nanoscale-diameter particles such as liposomes and dendrimers may be conscribed for the effective and safe administration of several drugs. The main advantages of nanosystem-mediated drug delivery are the following; i) sufficient absorption, ii) delayed metabolism and excretion, iii) longer half-life, iv) ability to cross several anatomical barriers, v) enhanced accumulation in specific target-tissues (e.g. malignant tumors), vi) lower toxicity of the drug. During the last years there is a growing interest around the potential contribution of Nanotechnology in the development of Nuclear Medicine and vice versa. Radioactive agents called radiopharmaceuticals are already ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288472</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288472</guid>        </item>
        <item>
            <title>Characterization of Peptide Polymer Interactions in Poly(alkylcyanoacrylate) Nanoparticles: A Mass Spectrometric Approach.</title>
            <link>http://www.medworm.com/index.php?rid=3288471&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158486%26dopt%3DAbstract</link>
            <description>Authors: Kafka AP, Kleffmann T, Rades T, McDowell A
    Drug/polymer interactions occur during in situ polymerization of poly(alkylcyanoacrylate) (PACA) formulations. We have used MALDI ionization coupled tandem time-of-flight (TOF) mass spectrometry as an accurate method to characterize covalent peptide/polymer interactions of PACA nanoparticles with the bioactives D-Lys6-GnRH, insulin, [Asn1-Val5]-angiotensin II, and fragments of insulin-like growth factor 1 (IGF-1 (1-3)) and human adrenocorticotropic hormone (h-ACTH, (18-39)) at the molecular level. Covalent interactions of peptide with alkylcyanoacrylate were identified for D-Lys6-GnRH, [Asn1-Val5]-angiotensin II and IGF-1 (1-3). D-Lys6-GnRH and [Asn1-Val5]-angiotensin II were modified at their histidine side chain within the peptide, ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288471</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288471</guid>        </item>
        <item>
            <title>Biodistribution and Pharmacokinetics of PEG-10kDa-Cholecystokinin-10 in Rats after Different Routes of Administration.</title>
            <link>http://www.medworm.com/index.php?rid=3288470&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158487%26dopt%3DAbstract</link>
            <description>Authors: Le&amp;#xF3;n-Tamariz F, Verbaeys I, Van Boven M, De Cuyper M, Buyse J, de Witte P, Verbruggen A, Cokelaere M
    Cholecystokinin, produced in the proximal small intestine, is a short acting satiating peptide hormone. CCK-10, before and after mono-iodination, was previously coupled to 10kDa polyethylene glycol (PEG). The formed conjugates PEG10kDa-CCK-10 and PEG10kDa-[(127)I]-CCK-10 show after i.p. administration to rats a sustained food intake reduction during 8h in comparison to 2h for free CCK-10. The present study examined the blood pharmacokinetics of this pharmacological interesting molecule by means of PEG10kDa-[(123)I]-CCK-10 following intravenous, intraperitoneal, intramuscular and nasal administration and the biodistribution after i.p. administration. HPLC analysis with radi...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288470</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288470</guid>        </item>
        <item>
            <title>Dextran Carrier Macromolecule for Colon Specific Delivery of Celecoxib.</title>
            <link>http://www.medworm.com/index.php?rid=3288469&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158488%26dopt%3DAbstract</link>
            <description>Authors: Shrivastava PK, Shrivastava SK
    The colon specific polymeric conjugates of celecoxib were prepared with dextran of different molecular weight Mr approximately 40 000, 70 000, and 100 000 (CSD-40, CSD-70 and CSD-100). Succinic acid was used as linker between the drug and dextran. The prepared conjugates were characterized by UV, IR, 1H NMR and HPLC. The maximum degree of substitution 3.9+/-0.20 % was found with the dextran CSD-100 conjugates. The percent release of drug obtained by in-vitro hydrolysis studies, was found to be 24.37+/- 0.6, 23.0 +/- 0.5 and 20.13+/- 0.8 in simulated colonic fluid (SCF) pH 6.8 while 17.90 +/- 0.4, 16.8+/- 0.75 and 15.47 +/- 0.5 in simulated intestinal fluid (SIF) pH 7.4 for CSD-40, CSD-70 and CSD-100, respectively, in both medium. The drug release...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288469</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288469</guid>        </item>
        <item>
            <title>Sustained Release of Verapamil Hydrochloride from Sodium Alginate Microcapsules.</title>
            <link>http://www.medworm.com/index.php?rid=3288468&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158489%26dopt%3DAbstract</link>
            <description>The objective of the present study was to develop sustained release microcapsules of verapamil hydrochloride (VH) using biodegradable polymers. For this purpose microcapsules embedded verapamil hydrochloride were prepared using sodium alginate alone and also by incorporating some co polymers like methyl cellulose (MC), sodium carboxy methyl cellulose (SCMC) , poly vinyl pyrollidone (PVP) and xanthan gum by employing complex emulsion method of microencapsulation. Microcapsules were prepared in various core: coat ratios to know the effect of polymer and co polymers on drug release. Overall ten formulations were prepared and evaluated for flow behaviour, sieve analysis, drug entrapment efficiency, in vitro dissolution studies, stability studies, including scanning electron microscopy and DSC....</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288468</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288468</guid>        </item>
        <item>
            <title>Electroporation: An Avenue for Transdermal Drug Delivery.</title>
            <link>http://www.medworm.com/index.php?rid=3288467&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158490%26dopt%3DAbstract</link>
            <description>Authors: Charoo NA, Rahman Z, Repka MA, Murthy SN
    The stratum corneum (SC) is a primary rate limiting barrier to permeation of drug molecules through the skin. Small molecular weight lipophilic drugs that are effective at low doses can be effectively delivered by passive transdermal delivery. The SC does not permit passage of polar/hydrophilic and macromolecules. Passive and physical penetration enhancements strategies are used to overcome this barrier property of the SC. Passive penetration enhancement techniques include use of supersaturated solutions and penetration enhancers. In general, the drug delivery potential of chemical modalities is limited. Therefore, physical permeation enhancement techniques gained a lot of focus in the recent past. Physical penetration enhancement techn...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288467</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288467</guid>        </item>
        <item>
            <title>Isolation and Physicochemical Characterization of Assam Bora Rice Starch for use as a Plasma Volume Expander.</title>
            <link>http://www.medworm.com/index.php?rid=3288466&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20158491%26dopt%3DAbstract</link>
            <description>Authors: Ahmad MZ
    Water soluble polysaccharides are most effective oncotic agents which are used for treatment of intravascular volume deficiency. Nowadays, they are used as basic material for plasma volume expander. Plasma volume expander based on starch has lower tendency to remain in any major organ of body in comparison to other plasma volume expander. Branched component of starch amylopectin is very similar in structure to glycogen, the reserve polysaccharides of animal; for all this reason starch is compatible with body tissues. Physicochemical properties of raw starch and amylopectin, isolated from Assam Bora rice were characterized for use as plasma volume expander. Characterization involves the determination of ash value, weight average molecular mass, viscosity and resistance...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3288466</comments>
            <pubDate>Wed, 17 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3288466</guid>        </item>
        <item>
            <title>Floating Controlled Drug Delivery System of Famotidine Loaded Hollow Microspheres (Microballoons) in the Stomach.</title>
            <link>http://www.medworm.com/index.php?rid=3143218&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20044907%26dopt%3DAbstract</link>
            <description>Authors: Ramachandran S, Shaheedha SM, Thirumurugan G, Dhanaraju MD
    Most of the floating systems have an inherent drawback of high variability in the GI transit time, invariably affecting the bioavailability of drug. An attempt has been made to develop floating drug delivery system for improving the drug bioavailability by prolongation of gastric residence time of famotidine in stomach. The floating microballoons were prepared using polymer Eudragit L-100 by solvent evaporation and diffusion technique. The prepared famotidine loaded microspheres were characterised for drug loading, entrapment, encapsulation efficiency, particle size distribution, surface morphology, differential scanning calorimetry, test for buoyancy, in-vitro release and in-vivo antiulcer studies. The results showed ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3143218</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3143218</guid>        </item>
        <item>
            <title>Formulation Optimization of Etoposide Loaded PLGA Nanoparticles by Double Factorial Design and their Evaluation.</title>
            <link>http://www.medworm.com/index.php?rid=3143217&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20044908%26dopt%3DAbstract</link>
            <description>Authors: Yadav KS, Sawant KK
    Etoposide is one of the most commonly used drugs in chemotherapy of acute lymphocytic leukemia and acute myelogenous leukaemia. Etoposide has variable oral bioavailability ranging from 24-74% and has terminal half life of 1.5 hours by intravenous route. The conventional parenteral therapy causes inconvenience and pain to the patients as it has to be given through a continuous IV infusion over 24-34 h. The present investigation was aimed at developing etoposide loaded biodegradable nanoparticles which would be a sustained release formulation and replace the conventional therapy of continuous intravenous administration. Nanoparticles were prepared by emulsion solvent evaporation method using high pressure homogenization. The process parameters like homogeniza...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3143217</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3143217</guid>        </item>
        <item>
            <title>Development of Repaglinide Loaded Solid Lipid Nanocarrier: Selection of Fabrication Method.</title>
            <link>http://www.medworm.com/index.php?rid=3143216&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20044909%26dopt%3DAbstract</link>
            <description>Authors: Rawat MK, Jain A, Mishra A, Muthu MS, Singh S
    Repaglinide solid lipid nanoparticles (RG-SLN) were fabricated using stearic acid as lipid. Pluronic F68 (PLF68) and soya lecithin were used as a stabilizer. SLNs were prepared by modified solvent injection and ultrasonication methods. SLNs prepared with modified solvent injection method have larger particle size (360+/-2.5nm) than prepared with ultrasonication method (281+/-5.3nm). The zeta potential of the prepared formulations by these two methods varied from - 23.10 +/-1.23 to -26.01 +/-0.89 mV. The maximum entrapment efficiency (62.14 +/-1.29%) was obtained in modified solvent injection method. The total drug content was nearly same (98%) in both the methods. In vitro release studies were performed in phosphate buffer (pH 6.8)...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3143216</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3143216</guid>        </item>
        <item>
            <title>Hexosomes: A Novel Drug Delivery System.</title>
            <link>http://www.medworm.com/index.php?rid=3143215&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20044910%26dopt%3DAbstract</link>
            <description>This article includes various methods of preparation of hexosomes and their application in drug delivery through various routes.
    PMID: 20044910 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3143215</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3143215</guid>        </item>
        <item>
            <title>Two-Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome.</title>
            <link>http://www.medworm.com/index.php?rid=2944730&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863481%26dopt%3DAbstract</link>
            <description>Conclusions: Intravesically injected BoNT/A is effective and safe in the medium-term management of patients with PBS. As the beneficial effect decreased progressively within a few months after treatment, repeat injections of the neurotoxin were needed over time.
    PMID: 19863481 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944730</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944730</guid>        </item>
        <item>
            <title>Gestational Exposure to Antidepressants and the Risk of Spontaneous Abortion: A Review.</title>
            <link>http://www.medworm.com/index.php?rid=2944729&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863482%26dopt%3DAbstract</link>
            <description>Conclusions. This review suggests that gestational exposure to antidepressants, especially paroxetine and venlafaxine, can lead to spontaneous abortion.
    PMID: 19863482 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944729</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944729</guid>        </item>
        <item>
            <title>The Potential of Polyphosphazenes for Delivery of Vaccine Antigens and Immunotherapeutic Agents.</title>
            <link>http://www.medworm.com/index.php?rid=2944728&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863483%26dopt%3DAbstract</link>
            <description>Authors: Eng NF, Garlapati S, Gerdts V, Potter A, Babiuk LA, Mutwiri GK
    Polyphosphazene polyelectrolytes are synthetic, biodegradable polymers that have shown great potential in vaccine and drug delivery applications. Numerous investigations in laboratory animals have revealed that polyphosphazenes are also potent immunological adjuvants that can dramatically enhance the magnitude, quality and duration of immune responses to a variety of bacterial and viral vaccine antigens. Evidence is accumulating that these polymers have potent adjuvant activity in large animals as well. Interestingly, polyphosphazenes can be combined with novel immune modulatory agents resulting in even more potent immune activity and protection against experimental infection. While most reports are on the activity...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944728</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944728</guid>        </item>
        <item>
            <title>Development of Taste Masked Fast Disintegrating Films of Levocetirizine Dihydrochloride for Oral Use.</title>
            <link>http://www.medworm.com/index.php?rid=2944727&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863484%26dopt%3DAbstract</link>
            <description>Authors: Mahesh A, Shastri N, Sadanandam M
    Fast disintegrating films of levocetirizine dihydrochloride useful for the treatment of acute allergic rhinitis and chronic urticaria have been developed by using the taste masking ability of cyclodextrins. The fast disintegrating films were prepared by solvent casting method. The films contained water-soluble polymers such as Kollicoat IR or pullulan, aspartame and sucralose as sweeteners and pre-gelatinized starch as disintegrant. Levocetirizine dihydrochloride was incorporated into these films by in-situ complex formation with hydroxy beta;-propyl beta;-cyclodextrin. The optimized films were evaluated for weight variation, film thickness, folding endurance, tackiness, tensile strength, assay, content uniformity, in vitro disintegration and ...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944727</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944727</guid>        </item>
        <item>
            <title>A Mathematical Approach for the Simultaneous In Vitro Spectrophotometric Analysis of Rifampicin and Isoniazid from Modified-Release Anti-TB Drug Delivery Systems.</title>
            <link>http://www.medworm.com/index.php?rid=2944726&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863485%26dopt%3DAbstract</link>
            <description>Authors: du Toit L, Pillay V, Choonara Y
    Dissolution testing with subsequent analysis is considered as an imperative tool for quality evaluation of the combination rifampicin-isoniazid (RIF-INH) combination. Partial least squares (PLS) regression has been successfully undertaken to select suitable predictor variables and to identify outliers for the generation of equations for RIF and INH determination in fixed-dose combinations (FDCs). The aim of this investigation was to ascertain the applicability of the described technique in testing a novel oral FDC anti-TB drug delivery system and currently available two-drug FDCs, in comparison to the United States Pharmacopeial method for analysis of RIF and INH Capsules with chromatographic determination of INH and colorimetric RIF determinati...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944726</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944726</guid>        </item>
        <item>
            <title>Preparation, Optimisation and Characterisation of Lyophilised Rapid Disintegrating Tablets Based on Gelatin and Saccharide.</title>
            <link>http://www.medworm.com/index.php?rid=2944725&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863486%26dopt%3DAbstract</link>
            <description>Authors: Alhusban F, Perrie Y, Mohammed AR
    Despite recent success, rapidly disintegrating lyophilized tablets still face problems of low mechanical strength and higher disintegration times resulting in poor patient compliance. The aim of the current work was to carry out a systematic study to understand the factors controlling mechanical properties of these formulations. The work investigated the influence of two bloom strengths of gelatin: low (60 bloom) and high (225 bloom) at different stock solution concentrations (2, 5, 7.5, and 10 %w/w). This was followed by investigation of addition of five saccharides (xylitol, glucose, trehalose, maltotriose and mannitol) at varied concentration range (10-80 %w/w) to decipher their influence on disintegration time, mechanical and thermal prope...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944725</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944725</guid>        </item>
        <item>
            <title>Formulation of Controlled Release Gellan Gum Macro Beads of Amoxicillin.</title>
            <link>http://www.medworm.com/index.php?rid=2944724&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863487%26dopt%3DAbstract</link>
            <description>Authors: Babu RJ, Sathigari S, Kumar MT, Pandit JK
    Gellan gum has been reported to have wide pharmaceutical applications such as tablet binder, disintegrant, gelling agent and as a controlled release polymer. Multiparticulate delivery systems spread out more uniformly in the gastrointestinal tract and reduce the local irritation. The purpose of this study is to explore possible applicability of gellan macro beads as an oral controlled release system of a sparingly soluble drug, amoxicillin. Gellan gum beads were prepared by ionotropic gelation with calcium ions. The effect of drug loading, stirring time, polymer concentration, electrolyte (CaCl2) concentration, curing time etc. influencing the preparation of the gellan gum macro beads and the drug release from gellan gum beads were inv...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944724</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944724</guid>        </item>
        <item>
            <title>Development of Conformational Mimetics of Conserved Streptococcus Pyogenes Minimal Epitope as Vaccine Candidates.</title>
            <link>http://www.medworm.com/index.php?rid=2944723&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863488%26dopt%3DAbstract</link>
            <description>Authors: Zhong W, Skwarczynski M, Toth I
    One of the factors responsible for the poor immunogenicity of synthetic peptide antigens is the lack of conformational integrity. Embedding the minimal epitopes in helix-promoting peptide sequences has successfully enhanced the immunogenicity of the epitopes derived from the alpha-helical regions of the M protein of group A streptococci (Streptococcus pyogenes, GAS). However, the introduction of &quot;foreign&quot; peptide sequences is believed to have an unfavourable impact on the antigen specificity. In the current study, we employed a non-peptide approach, using topological carbohydrate templates, to induce helical conformation of the peptide antigens. Utilized together with the advances of the lipid core peptide system and chemoselective ligation, fiv...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944723</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944723</guid>        </item>
        <item>
            <title>Application of Simplex Lattice Design and Desirability Function for the Formulation Development of Mouth Dissolving Film of Salbutamol Sulphate.</title>
            <link>http://www.medworm.com/index.php?rid=2944722&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863489%26dopt%3DAbstract</link>
            <description>Authors: Gohel MC, Parikh RK, Aghara PY, Nagori SA, Delvadia RR, Dabhi MR
    The aim of the present investigation was to prepare and optimize the formulation of mouth dissolving film of salbutamol sulphate by applying experimental design technique. The films were prepared using hydroxypropyl methylcellulose, polyvinyl pyrrolidone and polyvinyl alcohol by solvent evaporation technique. Simplex lattice design and desirability function were adopted for the preparation of film possessing desirable and optimized characteristics. Tensile strength, elastic modulus, percentage strain, load at yield, and percentage drug release were selected as dependent variables. Regression equations and contour plots were used to relate the dependent and independent variables. The concept of similarity factor S...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944722</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944722</guid>        </item>
        <item>
            <title>Development and Evaluation of In situ Gel Forming System for Sustained Delivery of Cyclosporine.</title>
            <link>http://www.medworm.com/index.php?rid=2944721&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863490%26dopt%3DAbstract</link>
            <description>Authors: Dhawan S, Kapil R, Kapoor DN, Kumar M
    Phase-sensitive in situ gel forming controlled release formulations of cyclosporine were prepared using poly (lactide-co-glycolide) and a solvent system consisting of various proportions of benzyl benzoate and benzyl alcohol. Uniformity of content of cyclosporine in the formulation and in vitro release samples was determined by radio immune assay (RIA). FTIR and CD spectroscopy ratified the conformational stability of cyclosporine in the formulation and in vitro release samples, respectively. Rheological properties of the formulations, assessed under isothermal conditions, showed dilatant behavior of all the formulations. In vivo studies were carried out on the optimized formulations vis-&amp;#xE0;-vis pure cyclosporine in rats and drug levels...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944721</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944721</guid>        </item>
        <item>
            <title>In Vitro and In Vivo Assessment of Matrix Type Transdermal Therapeutic System of Labetalol Hydrochloride.</title>
            <link>http://www.medworm.com/index.php?rid=2944720&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863491%26dopt%3DAbstract</link>
            <description>CONCLUSION: The above TTS holds promise for improved bioavailability and better management of hypertension on long term basis.
    PMID: 19863491 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944720</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944720</guid>        </item>
        <item>
            <title>Preparation and Characterization of Superporous Hydrogels as pH-Sensitive Drug Delivery System for Pantoprazole Sodium.</title>
            <link>http://www.medworm.com/index.php?rid=2944719&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863492%26dopt%3DAbstract</link>
            <description>The objective of the present study is to develop Superporous Hydrogel (SPH) and SPH composites (SPHC) as pH-sensitive drug delivery system for Pantaprazole sodium. In this investigation, Superporous hydrogels containing poly(methacrylic acid-co-acrylamide) with interconnected pores of several hundreds of micrometer were prepared using radical polymerization of methacrylic acid and acrylamide in the presence of N,N-methylene-bis-acrylamide as crosslinking agent. A gas blowing method using bicarbonate as a foaming agent was applied to introduce the porous structure. SPH composite polymers were made in the same way, except for using Ac-Di-Sol as a stabilizer. The structures of the SPH and SPH composites were characterized by FT-IR and Scanning electron microscopy (SEM). Apparent density and s...</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944719</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944719</guid>        </item>
        <item>
            <title>Gastroretentive Drug Delivery of Metformin Hydrochloride: Formulation and In Vitro Evaluation using 32 Full Factorial Design.</title>
            <link>http://www.medworm.com/index.php?rid=2944718&amp;cid=s_37273_13_f&amp;fid=37273&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19863493%26dopt%3DAbstract</link>
            <description>This study indicated that the MF GR tablets prepared using sodium alginate and sodium carboxymethylcellulose can successfully be employed as a once-a-day oral controlled release drug delivery system.
    PMID: 19863493 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)</description>
            <author>Current Drug Delivery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2944718</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2944718</guid>        </item>
    </channel>
</rss>

